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Abstract
Background
Following a reduction in global child mortality due to communicable diseases, the relative
contribution of congenital anomalies to child mortality is increasing. Although infant survival
of children born with congenital anomalies has improved for many anomaly types in recent
decades, there is less evidence on survival beyond infancy. We aimed to systematically
review, summarise, and quantify the existing population-based data on long-term survival of
individuals born with specific major congenital anomalies and examine the factors associ-
ated with survival.
Methods and findings
Seven electronic databases (Medline, Embase, Scopus, PsycINFO, CINAHL, ProQuest
Natural, and Biological Science Collections), reference lists, and citations of the included
articles for studies published 1 January 1995 to 30 April 2020 were searched. Screening for
eligibility, data extraction, and quality appraisal were performed in duplicate. We included
original population-based studies that reported long-term survival (beyond 1 year of life) of
children born with a major congenital anomaly with the follow-up starting from birth that were
published in the English language as peer-reviewed papers. Studies on congenital heart
defects (CHDs) were excluded because of a recent systematic review of population-based
studies of CHD survival. Meta-analysis was performed to pool survival estimates, account-
ing for trends over time. Of 10,888 identified articles, 55 (n = 367,801 live births) met the
inclusion criteria and were summarised narratively, 41 studies (n = 54,676) investigating
eight congenital anomaly types (spina bifida [n = 7,422], encephalocele [n = 1,562], oeso-
phageal atresia [n = 6,303], biliary atresia [n = 3,877], diaphragmatic hernia [n = 6,176], gas-
troschisis [n = 4,845], Down syndrome by presence of CHD [n = 22,317], and trisomy 18 [n
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= 2,174]) were included in the meta-analysis. These studies covered birth years from 1970
to 2015. Survival for children with spina bifida, oesophageal atresia, biliary atresia, diaphrag-
matic hernia, gastroschisis, and Down syndrome with an associated CHD has significantly
improved over time, with the pooled odds ratios (ORs) of surviving per 10-year increase in
birth year being OR = 1.34 (95% confidence interval [95% CI] 1.24–1.46), OR = 1.50 (95%
CI 1.38–1.62), OR = 1.62 (95% CI 1.28–2.05), OR = 1.57 (95% CI 1.37–1.81), OR = 1.24
(95% CI 1.02–1.5), and OR = 1.99 (95% CI 1.67–2.37), respectively (p < 0.001 for all, except
for gastroschisis [p = 0.029]). There was no observed improvement for children with ence-
phalocele (OR = 0.98, 95% CI 0.95–1.01, p = 0.19) and children with biliary atresia surviving
with native liver (OR = 0.96, 95% CI 0.88–1.03, p = 0.26). The presence of additional struc-
tural anomalies, low birth weight, and earlier year of birth were the most commonly reported
predictors of reduced survival for any congenital anomaly type. The main limitation of the
meta-analysis was the small number of studies and the small size of the cohorts, which lim-
ited the predictive capabilities of the models resulting in wide confidence intervals.
Conclusions
This systematic review and meta-analysis summarises estimates of long-term survival
associated with major congenital anomalies. We report a significant improvement in survival
of children with specific congenital anomalies over the last few decades and predict survival
estimates up to 20 years of age for those born in 2020. This information is important for the
planning and delivery of specialised medical, social, and education services and for counsel-
ling affected families. This trial was registered on the PROSPERO database
(CRD42017074675).
Author summary
Why was this study done?
• Following a reduction in global child mortality due to communicable diseases, the rela-
tive contribution of congenital anomalies to child mortality under age 5 years is increas-
ing globally.
• Identifying and addressing the emerging priority of congenital anomalies, including for
children aged 5–9 years, is one of the strategic directions for the post-2015 child health
agenda.
• This research aimed to summarise and quantify the existing population-based evidence
on long-term survival of children born with specific major congenital anomalies that
manifest in childhood.
What did the researchers do and find?
• This systematic review included 55 international studies that estimated survival beyond
1 year of age of children born with major congenital anomalies.
• Our meta-analysis results of 41 studies over the birth years 1970–2015 showed a statisti-
cally significant improvement in survival over time in children with spina bifida,
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oesophageal atresia, biliary atresia, congenital diaphragmatic hernia, gastroschisis, and
Down syndrome associated with a congenital heart defect, but there was no evidence of
improvement in those with encephalocele or biliary atresia with a native liver.
• The commonest significant independent predictors of reduced survival for any congeni-
tal anomaly type were presence of additional structural anomalies, low birth weight, and
earlier birth year period.
What do these findings mean?
• A significant improvement in survival of children with specific congenital anomalies
over the last few decades reported by individual studies and identified by the meta-anal-
ysis has important public health, medical, social, and family implications.
• Information on predicted survival of children with congenital anomalies up to 20 years
of age is important for planning specialised medical, social, and education services for
these children and for estimating costs associated with special care needs in childhood
and adulthood.
Introduction
Globally, mortality in children aged under 5 years has halved since 1990, mainly because of a
sharp reduction in deaths from communicable diseases as a result of targeted child health strat-
egies and interventions of the United Nations (UN) Millennium Development Goals [1]. Fol-
lowing this worldwide reduction, the relative contribution of congenital anomalies to child
mortality is increasing globally and is therefore outlined as an emerging priority to be
addressed by the UN Sustainable Development Goals in the post-2015 child health agenda [2].
Although the contribution of congenital anomalies to infant mortality is well described, in par-
ticular for developed countries [3–5], there is less research focused on survival beyond the first
year of life. However, this is of considerable public health importance, as according to evidence
from North America and Europe, the mortality rate of individuals born with congenital anom-
alies significantly exceeds that of the general population after infancy as well [6–9]. In addition,
a large variation in child death rates still exists between countries, even within Europe [10]. In
2012, the child death rates (age 0–14 years) were about 60% higher in the United Kingdom
and Belgium compared to Sweden, with an additional 10 Western European countries being
30% higher than Sweden [10]. Currently, a quantitative summary of population-based studies
of survival beyond infancy for specific congenital anomalies is lacking. Accurate estimates of
long-term survival are important for clinicians counselling parents when a congenital anomaly
is diagnosed pre- or postnatally and for public health commissioners to ensure adequate
resources are in place to provide high-quality medical and social care for these individuals.
Importantly, it is essential that estimates are provided according to type of congenital anomaly,
given the diversity in aetiology, treatment, and prognosis.
We performed a systematic review and meta-analysis to summarise and quantify the exist-
ing population-based data on long-term survival (beyond infancy) of individuals born with
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specific major congenital anomalies that manifest in childhood and explore the risk factors
associated with survival.
Methods
Search strategy
This study is reported as per the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guideline (S1 PRISMA Checklist). A protocol for this systematic review
was registered on the International Prospective Register of Systematic Reviews (PROSPERO)
database (CRD42017074675) (S1 Text). We conducted comprehensive literature searches
using a combination of the following sources of information:
1. Electronic bibliographical databases: MEDLINE, EMBASE, Scopus, PsycINFO, CINAHL,
ProQuest Natural, and Biological Science Collections and also the databases of the system-
atic reviews, i.e., PROSPERO, the JBI Database of Systematic Reviews and Implementation
Reports. We used key words and subject headings (dependent on the database) combining
the keywords for the population (birth, pregnancy, delivery), exposure (congenital anom-
aly, including specific anomaly groups), outcome (long-term survival, mortality), and study
design (population-based studies), incorporating elements of the PICOS (Population/
Patient, Intervention/Exposure, Comparator group, Outcome, Study design) framework
into our systematic search strategy [11] (S1 Table). The final search results were limited to
English papers and to humans, whereas the initial searches had no language limitations to
examine whether there were any relevant studies we could have missed. We have identified
66 papers published in non-English language (79% from Europe) based on Medline search,
but no papers met our inclusion criteria.
2. Manual searching of the reference lists of the included full papers and of the relevant previ-
ous literature reviews, including systematic, was performed.
3. Citation searching for studies that had referenced the included studies was performed via
the Google Scholar citation function.
4. Keyword searches in key journals, including Birth Defects Research, Archives of Disease in
Childhood, Pediatrics, The Journal of Pediatrics, and Journal of Pediatric Surgery, were also
undertaken.
5. Authors were contacted if there was insufficient information to decide whether the study
met the inclusion criteria or if additional information for the inclusion in the meta-analysis
was needed.
6. Reference lists and citations of any new articles identified were further searched for any
additional studies in the iterative process until no new studies were identified. Database
searches were completed in March 2019 and updated in May 2020.
SVG conducted all searches and screened the titles and abstracts of all the identified records
according to the inclusion criteria, and three other authors (MS, AC, JR) independently
screened a random 10% sample of the records using the Rayyan software for systematic
reviews [12]. Any discrepancies (n = 4) in the included studies were discussed amongst all
authors and agreement reached.
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Definitions and classification of congenital anomalies
Major congenital anomalies in the included studies were classified according to the Interna-
tional Classification of Disease (ICD) revision 8 (ICD-8) [8], ICD-9 (majority of papers), ICD-
10 [13–15], and British Paediatric Association (BPA-ICD-9) diagnosis coding [16–20] or sur-
gical codes [21]. Some papers that included a long birth year period used more than one ICD
version for the corresponding time periods [9,22–25]. The included studies reported the sur-
vival estimates for all congenital anomalies combined (e.g., ICD-9 codes 740.0–759.9) and/or
by congenital anomaly group (the system affected, e.g., urinary system, ICD-9 753.0–753.9)
and/or subtype (the individual disorder, e.g., spina bifida, ICD-9 741). Some European studies
[14,15,17] classified major congenital anomalies according to European Surveillance of Con-
genital Anomalies (EUROCAT) guidelines [26,27]. We have presented the congenital anomaly
subtypes within the major congenital anomaly groups according to the EUROCAT classifica-
tion [26].
Eligibility criteria
Studies meeting the following criteria were included: (1) being an original population-based
peer-reviewed study that reported long-term (beyond 1 year of life) survival of children born
with a major congenital anomaly that manifests in childhood; (2) reporting survival probabil-
ity (or the number of patients born and the number or proportion alive at age>1 year) for
these children that were followed up from birth; (3) being published from 1 January 1995 to 30
April 2020 to increase comparability of included birth cohorts in relation to medical care and
treatment availability/policies; (4) involving humans only and published in the English
language.
Studies were excluded if (1) they reported survival during the first year of life only; (2)
patients were not followed up from birth, because this may have under-ascertained deaths
occurring prior to follow-up (e.g., if follow-up began after surgical correction); (3) they were
not population-based, as other study designs are more likely to incur ascertainment bias (e.g.,
hospital-based studies may capture more severe phenotypes); (4) they focused on individuals
born with congenital heart defect (CHD), because there was a recently published systematic
review covering these population-based studies [28]; (5) they followed up a restricted subgroup
of patients (e.g., preterm births only or extracorporeal membrane oxygenation [ECMO]
patients only). No exclusions were made based on the birth year of studied cohorts.
Data extraction
Information on the following study characteristics was extracted: study location, birth year
period, duration of follow-up/years of survival, congenital anomaly type and if isolated/non-
isolated, sources of case ascertainment (e.g., congenital anomaly register) and sources of death
identification (e.g., linkage with a mortality database), number of cases and deaths, Kaplan-
Meier survival estimates reported, or the survival estimates calculated by the reviewers.
Authors were contacted if survival estimates were reported for subgroups of patients only (e.g.,
by sex or age at operation), if it was not possible to calculate 95% confidence intervals (95%
CIs) or extract survival estimates from the Kaplan-Meier curves, or if further information was
required or clarification needed (n = 18). If the authors did not respond after two reminders or
if the study was closed and access to the data was not possible, we calculated the lower and
upper limits of the 95% CI according to the efficient-score method (corrected for continuity)
described by Newcombe, 1998 [29], based on the procedure outlined by Wilson, 1927 [30]
(http://www.vassarstats.net/survival.html). If survival estimates were not reported in the text
or tables of the included paper, they were extracted from Kaplan-Meier survival curves, where
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available, using PlotDigitizer software [31]. If none of the above was possible, the study was
excluded.
Data extraction and quality appraisal of the included studies were performed in duplicate,
i.e., all by SVG and a subset of studies by each coauthor. Data were entered into piloted data
extraction forms (S2 Table).
Statistical analysis
Where three or more articles reported survival with the number of births (or where the num-
bers of births could be estimated from the 95% CIs provided) for a specific congenital anom-
aly, a meta-analysis was performed to estimate pooled survival at ages 1, 5, 10, and 20 (and 25,
where available) years. The Stata program “gllamm” was used to fit univariate multilevel meta-
analysis of longitudinal data to allow for the correlations in survival over several time periods
within studies [32,33]. Survival according to age (0–25 years) was modelled using the logistic
regression options within the gllamm program: family(binomial) and link(logit). The outcome
of interest was the number of deaths occurring out of the total number of live births. The num-
ber of deaths at each time point, if not provided, was estimated from the published proportions
surviving and the number of live births by assuming there was no loss to follow-up. Calculat-
ing the number of deaths in this way will be unbiased (as the proportion surviving is unbiased)
but will result in slightly too narrow confidence intervals. To confirm that this is valid, an alter-
native method using the arcsine square root transformation [34] of the published survival esti-
mate was applied and the estimated standard error was calculated, and a model was fitted in
gllamm using the weighted regression options instead of the logistic regression above. Both
methods reported consistent results, and hence, the results of the logistic regression models
are reported here, as they enable the interpretation of the odds of increasing survival over
time. Studies were treated as a random effect and cohort of birth and age at survival as fixed
effects nested within the studies. Age was modelled as a continuous variable using a linear
term or, where significant (according to a likelihood ratio test), a quadratic term. Cohort of
birth was modelled as a continuous variable. Most included studies reported survival across
distinct periods (e.g., between 2000 and 2009), so the mean year of birth was used (e.g., 2005).
For studies that reported survival estimates for multiple cohorts (e.g., 2000–2004, 2005–2009),
survival for both cohorts were entered into the model, again with average year of birth for each
cohort (e.g., 2002 and 2007). Using the models, survival at ages 1, 5, 10, 20, and 25 years was
estimated for patients born in 2000 and 2020. Models were fitted separately for each type of
congenital anomaly. Odds ratios (ORs) representing the increase/decrease in survival per
10-year increase in time were extracted from the models. Where fewer than three studies
reported survival for a specific congenital anomaly, the survival estimates were discussed nar-
ratively. The ages for which more than three studies reported a survival rate were plotted sepa-
rately; often, the reports were at 5 or 10 years of age. This allows the reader to evaluate the
changes that have occurred over time in the survival of the children up to 5 years of age and
separately up to 10 years of age. All modelled survival curves, although plotted on two separate
figures, are derived from the one model fitted on all the data.
Analysis was performed in Stata 15 (StataCorp), and p< 0.05 was considered statistically
significant.
Quality appraisal
The Newcastle-Ottawa Quality Assessment Scale (NOS) for cohort studies [35] was used to
assess the quality of the included studies. The scale assesses information bias, selection bias,
and confounding (S2 Table). Although a traditional cohort study can be awarded a maximum
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of nine stars, for survival population-based studies a comparison group is not a mandatory
component of the study design; therefore, a maximum of six stars can be allocated to the
majority of the included studies (S3 Table).
Results
Search results
A total of 10,888 records identified from the electronic database searches and other sources
were available for screening titles and abstracts (Fig 1). After excluding 10,660 records, 228
were eligible for full text review. After further exclusion of 173 articles, 55 met the inclusion
criteria, covering a total population of 367,801 live births with various types of major congeni-
tal anomalies. Earlier follow-up studies based on the same population were replaced by more
recent ones if they also reported survival at a younger age (n = 2 [36,37]). However, if survival
at a more advanced age only was reported in the later article [38], the earlier article was also
included (n = 1 [39]).
Characteristics of included studies
Table 1 provides the description of 55 studies included in this review. Further detail on the
sources of case ascertainment and death identification and the description of the comparison
group, if any, are given in S4 Table. Nine studies analysed long-term survival of all congenital
anomalies combined: seven with [6,8,15,17,40–42] and two without [7,43] stratification by
congenital anomaly group/subtype (Table 1). Other studies (n = 46) focused on specific groups
or subtypes of congenital anomalies: the central nervous system (n = 5 [44–49]), including
spina bifida [44–46,48,49] and encephaloele [44,47]; orofacial clefts (n = 1 [16]); anomalies of
the digestive system (n = 22), including oesophageal atresia [9,50,51], anorectal malformations
[52], congenital diaphragmatic hernia (CDH) [18,23,51,53,54], biliary atresia [36–39,55–64],
and Hirschsprung disease [24]; abdominal wall defects (n = 1 [21]); chromosomal anomalies
(n = 12), including trisomy 21 [14,19,22,65–69,70,71], trisomy 13 [25,72], and trisomy 18
[25,72]; skeletal dysplasias (n = 2 [13,20]); and Prader-Willi syndrome (PWS) (n = 1 [73]). The
included studies were conducted in Europe (n = 29 [8,9,13–15,17,21–24,36–39,44,45,50–
54,56–58,60,61,64,65,68]), the United States of America (n = 12 [7,18–20,40,41,43,46–
48,70,72]), Australia (n = 7 [16,42,59,66,67,69,73]), Canada (n = 3 [6,25,63]), Japan (n = 1
[62]), Brazil (n = 1 [55]), and Hong Kong (n = 1 [71]). One international study reported sur-
vival of children with spina bifida from a number of registries from Europe and the USA [49].
As all included studies were population-based, sources of case ascertainment for most studies
(n = 39) were congenital anomaly registers or surveillance programmes that either included all
types of major congenital anomalies or were anomaly-specific. The majority of these studies
linked their congenital anomaly data with death registration data to ascertain data on age at
death (S4 Table).
As our literature search was restricted to years between January 1995 and April 2020, the
publication years ranged between 1997 [68] and 2020 [71], whereas patients were mostly born
between 1970 and 2010, with the earliest birth year in 1950 [73] and the latest ending in June
2016 [58]. Table 1 also describes the duration of follow-up, the survival age analysed, and
whether survival was reported in the papers (with or without 95% CI) or estimated by our
reviewers. Table 1 also gives the NOS scores that range between 5 and 8 respective of the use of
the comparison group that is not mandatory for the survival studies (see S3 Table for detailed
scoring). According to NOS, all studies were of low risk of bias.
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Fig 1. PRISMA flowchart of searches, screening, and study selection. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
https://doi.org/10.1371/journal.pmed.1003356.g001
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Table 1. Description of included studies.
Author,
publication year,
reference,
location
Congenital anomaly (CA)
group/subtype
Birth year
period
Duration and
completeness of
follow-up (FU)
Inclusion of additional
anomalies/exclusions
Reporting of survival estimates Study
quality
total
score�
Agha, 2006 [6],
Ontario, Canada
All anomalies and by
group
1979–1986 10 years for all
anomalies
Multiple births excluded 1- and 5-year estimates by CA
group reported, 10-year survival
for all CAs extracted from Kaplan-
Meier (K-M) curves
9
Bakker, 2019 [49],
5 European and 4
USA registries‡
Spina bifida International
Classification of Diseases
Revision 10 (ICD-10) Q05
and ICD-9 741
2001–2012
(for 7 out of
8 included
registers)
Up to 5 and�5 years,
depending on the
registry
Only registries with FU
beyond 1 year and using
linkage to vital records
(n = 9) are included in this
review. Cases excluded
when present with
anencephaly. Both isolated
and syndromic cases are
included
Survival estimates calculated using
mortality rates reported
6
Bell, 2016 [16],
Western Australia
(WA)
Orofacial clefts 1980–2010 FU to 20 years for
1980–1992, low loss to
FU (approximately
2.8%)
Estimates for isolated and
those with additional CA
1-year estimates by cleft type (for
1980–2010 cohort) and 20-year
estimates (for 1980–1992) reported
8
Berger, 2003 [7],
Michigan, USA
All anomalies (not
stratified by group)
1992–1998 Up to 7 complete years
of FU (for those born
in 1992, 97%)
Multiple births excluded Reported mortality for each birth
year, survival estimated by
reviewer
8
Borgstedt-Bakke,
2017 [45], western
Denmark
Spina bifida
(myelomeningocele)
1 Jan 1970
to 30 Jun
2015
Up to 20 years,
censored on 9 Nov
2015; median age at
death: 1 year of age
Excluded cases with
incomplete mortality or
clinical data (n = 16)
Survival estimates extracted from
K-M curves by birth year period:
1970–1979, 1980–1989, and 1990–
2015
7
Brodwall, 2018
[22], Norway
Down syndrome (DS) 1994–2009 Complete FU to 5 years
for those traced (5.5%
lost to FU—censored)
Isolated DS and with
associated (congenital heart
defect [CHD] and/or
extracardiac malformation)
anomalies included
K-M survival estimates reported in
the paper or obtained from
authors on request
8
Burgos, 2017 [23],
Sweden
Congenital diaphragmatic
hernia (CDH)
1987–2013 FU up to 20 years for
the whole period, up to
10 years for 2000–2013,
complete for 98.7%
Patients who were
diagnosed of CDH after the
neonatal period were
excluded
1-year and overall (beyond 1 year)
mortality reported; 1-, 5-, and
10-year survival extracted from
K-M curves
6
Cassina, 2016 [50],
Northeast Italy
(NEI)
Oesophageal atresia (ICD-
9 750.3)
1981 to 31
July 2012
FU up to age 25 years
(minimum 3 months)
or censored at 31 Oct
2012, survival traced in
91.7% (330/360)
Chromosomal anomalies
(n = 42, 10.3%) excluded,
other non-isolated cases
included
Survival estimates reported for 1
and 25 years, for 5 and 10 years
extracted from K-M curves
6
Cassina, 2019 [52],
NEI
Anorectal malformations 1981–2014 Survival status was
traced for patients born
between 1 Jan 1990 and
31 Jul 2012 up to 20
years (88.2%)
Those with non-isolated
anomalies were included
(n = 216, 50.5%), isolated
(n = 212) included 7
patients with trisomy 21
Overall K-M survival estimates
(with 95% confidence interval
[95% CI]) reported for 1 and 20
years, for 10 years separately for
isolated and non-isolated
5
Chardot, 2013
[36], France
Biliary atresia (BA) 1986–2009 Median FU in survivors
9.5 years (range 3
months to 24.6 years)
Only cases with corrected
diagnosis of BA, including
those with BA splenic
malformation syndrome
(BASM)
K-M survival estimates reported
for 5, 10, 15, and 20 years, 95% CI
calculated using reported SE
6
Chua, 2020 [71],
Hong Kong
DS (ICD-9 code 758.0) 1995–2014 FU from birth until the
age of 5 years, up to 30
Jun 2017, or the date of
death (FU range 0.01–
22.0 years)
All with DS, with or without
associated anomalies
K-M survival estimates reported
for 6 months, 1 and 5 years
6
(Continued)
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Table 1. (Continued)
Author,
publication year,
reference,
location
Congenital anomaly (CA)
group/subtype
Birth year
period
Duration and
completeness of
follow-up (FU)
Inclusion of additional
anomalies/exclusions
Reporting of survival estimates Study
quality
total
score�
Dastgiri, 2003
[17], Glasgow,
Scotland
All anomalies and by
group
1980–1997 5 years’ FU for all (97%
complete)
Isolated anomalies only
included
K-M survival estimates reported
for 1 and 5 years and 95% CI
provided by authors on request
6
Davenport, 2011
[37], England and
Wales
BA 1999–2009 Vital status assessed in
Jan 2010—up to 10
years of age, none lost
to FU
BA cases with BASM and
other associated anomalies
(n = 84) included
Actuarial survival estimates
reported for 5 and 10 years,
extracted from survival curve for 4
years
6
De Carvalho, 2010
[55], Brazil
BA Jul 1982 to
Dec 2008
FU between Jul 1982
and Dec 2008, loss to
FU not reported
BA cases with BASM or
other associated anomalies
(n = 61) included
K-M survival estimates (without
95% CI) reported for 4 years
5
De Vries, 2011
[56], the
Netherlands
BA 1977–1988 20-year FU: median
23.8 (range 20.2–31.4),
2 lost to FU
All BA cases (including
BASM, n = 7) included, no
other anomalies reported
20-year survival reported 6
Eide, 2006 [8],
Norway
All anomalies and by
selected subgroup
1967–1979;
FU 1967–
1998
FU 18 years for all birth
years, 6.2% (n = 24,355)
untraceable from the
whole cohort of
393,570
Male patients and live
singleton births only
included. CAs ascertained
during the first week after
birth only, selection bias
possible
No survival analysis performed,
mortality by age 18 years (military
draft) reported, survival estimated
by reviewers assuming no
censoring
8
Folkestad, 2016
[13], Denmark
Osteogenesis imperfecta
(OI)
1977–2012 FU to 31 Dec 2013, up
to 20 years (for this
review)
All patients with OI
diagnosis on National
Patient Register included,
survival up to 20 years for
patients born from 1977
included in this review
Survival estimated by reviewers
using data on deaths and number
at risk provided by authors on
request
9
Frid, 1999 [65],
northern Sweden
DS 1973–1980,
FU 1973–
1997
Complete FU to age
14.5 years (n = 213,
95.1%)
All with DS, with or without
associated anomalies
Mortality reported, survival
estimated by reviewers
6
Garne, 2002 [51],
Funen County,
Denmark
Gastrointestinal anomalies
(atresias, abdominal wall
defects, and CHD)
1980–1993,
FU 1980–
98
FU of all patients to 5
years of age
All patients with and
without associated
anomalies
Number of deaths and survivors
reported, survival estimated by
reviewers
6
Glasson, 2016
[66], WA
DS 1980–2010,
censored to
end 2013
FU to 31 Dec 2013, up
to 25 years for birth
years 1980–2010
From the survival analysis,
deaths within the first 24
hours excluded (n = 11)
1-, 5-, 10-, 20-, and 25-year K-M
survival estimates with 95% CI
reported
7
Grizelj, 2010 [57],
Croatia
BA 1992–2006 FU to 31 Dec 2006,
(median 2.65 years,
range 0.2–14.3) (6.9%
[2/29] lost to FU)
1 inoperable patient
excluded from survival
analysis
K-M 5- and 10-year native liver
survival (NLS) estimates with 95%
CI reported; all deaths included by
reviewers for the overall survival
6
Gudbjartsson,
2008 [53], only
Iceland centre
included
CDH 1983–2002 FU 1983 to Apr 2005,
3-year FU of all
patients (mean FU 5
years)
Only early presenters
(diagnosed within first 24
hours, n = 19) included
3-year survival reported for early
presenters, overall survival
estimated by reviewers (n = 23)
6
Halliday, 2009
[67], Victoria,
Australia
DS 2 birth
cohorts:
1988–1990
and 1998–
2000
FU to 2005, 5-year FU
for all births (unless the
child died interstate;
percentage of
migration < 2%)
Patients with associated
anomalies (n = 121 in 1988–
1990 and n = 89 in 1998–
2000) included
K-M 5-year survival reported,
1-year survival estimated by
reviewers
6
Hayes, 1997 [68],
Dublin, Ireland
DS 1980–1989 FU data collected in
1992 (range 3–12 years)
(vital status unavailable
in 1.3%, n = 5)
Patients with associated
anomalies (n = 212)
included (data on additional
CAs available in 365/389,
93.6%)
K-M survival reported for 1980–
1989, and for 1980–1994 and
1985–1989
6
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Table 1. (Continued)
Author,
publication year,
reference,
location
Congenital anomaly (CA)
group/subtype
Birth year
period
Duration and
completeness of
follow-up (FU)
Inclusion of additional
anomalies/exclusions
Reporting of survival estimates Study
quality
total
score�
Hinton, 2017 [18],
Atlanta, USA
CDH 1979–2003 FU to death or
censored at 31 Dec
2006; 3-year survival
complete for all cases
Excluded children with
known chromosomal
anomalies or syndromes
K-M overall survival reported by
various factors, K-M survival
curves plotted for White and Black
ethnicity by birth period, poverty,
and CHD
6
Jaillard, 2003 [54],
France
CDH 1991–1998 FU to 2 years of all the
surviving infants with
CDH
Patients with associated
lethal CAs (n = 9) excluded
Early (<2 months) and late deaths
(between 2 months and 3 years)
reported, 2-year survival with 95%
CI estimated by reviewers
6
Kucik, 2013 [19],
10 regions, USA
DS 1983–2003 FU ranged from 9 to 22
years between the
regions (8 regions with
up to 11+ years, 4 with
20–22 years)
Cases with additional
anomalies (e.g., CHD)
included
K-M survival estimates with 95%
CI reported for 1, 5, 10, and 20
years
6
Lampela, 2012
[60], Finland
BA 1987–2010 FU to 4 full years for all
live births with BA
All BA cases included: with
BASM (n = 9, 14%), with
other anomalies (n = 6, 9%)
Actuarial 4-year survival estimates
reported and final figures provided
by author on request, 95% CI
calculated by reviewers
6
Leonard, 2000
[69], WA
DS 1980–1996 FU to 10 years for all
born in 1980–1985, to
10 years for 1986–1990,
and to 5 years for
1991–1996
Cases with additional
anomalies (e.g., CHD)
included
K-M 1-, 5-, and 10-year survival
estimates reported, overall and by
3 birth periods
6
Leonhardt, 2011
[61], Germany
BA 2001–2005 FU to 2 full years (16/
183 lost to FU, 8.7%)
All with BA diagnosis
included
2-year K-M survival estimates after
Kasai hepatoportoenterostomy
(KP) or liver transplantation
reported, overall survival
(including 3 initial deaths)
calculated by reviewers
5
Lionti, 2012 [73],
Victoria, Australia
Prader-Willi syndrome
(PWS)
1950 to 31
May 2010
FU to 35 years of age,
loss to FU not reported
Only patients with
diagnosed PWS included,
infant deaths may have been
missed by the register
K-M survival estimates with 95%
CI reported for 10, 20, 30, and 35
years, estimates for 1, 5, 15, and 25
years extracted from K-M curves
5
Lo¨f Granstro¨m,
2017 [24], Sweden
Hirschsprung disease
(HSCR)
1964–2013 FU to 31 Dec 2013 (up
to 50 years of age),
median 19 years (range
2–49), loss to FU not
reported†
Only those with confirmed
diagnosis of HSCR included
(n = 739), those with HSCR
and DS also included
K-M survival curves with 95% CI
presented up to 50 years, survival
estimates up to 25 years extracted
by reviewers
8
McKiernan, 2000
[39], UK and
Ireland
BA Mar 1993
to end Feb
1995
FU up to 5 years
(median 3.5 years,
range 0.3–5.4), lost to
FU 2.2%
Those with additional CAs
included (n = 20, n = 9
BASM)
Actuarial survival estimated by
K-M method and 5-year overall
survival and NLS reported
6
McKiernan, 2009
[38], UK and
Ireland
BA Mar 1993
to end Feb
1995
FU: median age at last
FU 12 years (range
0.25–14), only 2 lost to
FU (2.2%)
Those with additional CAs
included (n = 20, n = 9
BASM)
Actuarial survival estimated by
K-M method and 13-year overall
survival and NLS reported
6
Meyer, 2016 [72],
9 states, USA
Trisomy 13 and trisomy 18 1999–2007 FU 1999–2008, birth
years 1999–2005
included for survival
estimation to 5 years,
loss to FU not
reported†
All cytogenetic variants
included; different birth
years included in different
states
K-M survival estimates with 95%
CI (<28 days, <1 year, and <5
years) reported
6
(Continued)
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Table 1. (Continued)
Author,
publication year,
reference,
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Congenital anomaly (CA)
group/subtype
Birth year
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Duration and
completeness of
follow-up (FU)
Inclusion of additional
anomalies/exclusions
Reporting of survival estimates Study
quality
total
score�
Nelson, 2016 [25],
Ontario, Canada
Trisomy 13 and trisomy 18 1991–2012 FU 1991–2013, up to
7,000 days (1.6%, n = 7
lost to FU)
All cytogenetic variants
included (90.2%
unspecified, 3.5% mosaic,
6.3% translocation)
K-M survival estimates with 95%
CI for 1, 5, and 10 years reported
6
Nembhard, 2010
[43], Texas, USA
All CAs, not stratified by
group
1996–2003 FU to 2005, 5-year
survival analysed; loss
to FU not reported†
3.7% (unduplicated
n = 1,877) excluded:
trisomy 13 or 18 (n = 511);
not born to non-Hispanic
White (NHW), non-
Hispanic Black (NHB), or
Hispanic mother
(n = 1,340); deaths with no
date of death (n = 50)
5-year K-M survival estimates with
95% CI for NHW, NHB, and
Hispanic ethnicity for term and
preterm births reported and by
size at birth
6
Nio, 2003 [62],
Japan
BA 1989–1999 1989 only: compete FU
for 10-year survival;
1989–1994: complete
FU for 5-year survival,
2.6% lost to FU (n = 19)
BA cases with additional
anomalies included (19.6%
including n = 33 with
BASM)
5- and 10-year survival estimates
reported only for those birth years
with complete FU
6
Oddsberg, 2012
[9], Sweden
Oesophageal atresia 1964–2007 Complete FU of the
nationwide cohort by
birth year, up to 25
years for 1964–1969
(percentage missing
negligible)
Patients older than 1 year at
diagnosis excluded to avoid
misclassification; cases with
associated CAs included
K-M survival estimates up to 20
years by time period extracted
from K-M curves by reviewers
9
Pakarinen,2018
[58], Nordic
countries
BA 1 Jan 2005
to 30 Jun
2016
FU for at least 4
months, median 4.9
(IQR 1.8–7.9 years)
Noncurable CHD or central
nervous system CA (n = 4)
withdrawn from treatment
and excluded from the
survival analysis, other
associated CAs (n = 41,
BASM n = 19) included
K-M 5- and 10-year survival
estimates reported for 154
included cases, survival estimated
by reviewers based on all 158 BA
patients for consistency
6
Rankin, 2012 [14],
Northern England
DS 1985–2003 FU to 29 Jan 2008,
95.3% traced (669/702)
All live-born patients with
DS—full trisomy 21,
mosaicism, and
translocation—were
included
K-M survival estimates with 95%
CI reported for 1, 5, 10, and 20
years
6
Rasmussen, 2006
[70], Metropolitan
Atlanta, USA
DS 1979–1998 1979–1999, FU
complete for 1979–
1988 for 10-year
survival, censored by 20
years (loss to FU not
reported†)
47 (of 692) excluded:
cytogenetic results
unavailable (22), complex
rearrangements involving
chromosome 21 (7),
mosaicism (16), and not DS
(2)
K-M survival estimates with 95%
CI reported for 1 and 10 years, 5-
and 20-year estimates with 95% CI
extracted from K-M curves by
reviewers
6
Risby, 2017 [21],
southern
Denmark
Gastroschisis 1997–2009 FU to 5 years for the
whole cohort (between
Jun 2013 and Apr
2014)
All cases with gastroschisis
included
1- and 5-year survival estimated by
reviewers using mortality data
6
Schneuer, 2019
[42], New South
Wales (NSW),
Australia
All anomalies, by group
and subtype by European
Surveillance of Congenital
Anomalies (EUROCAT)
classification
2004–2009 FU to death, 5 years of
age, or until 31 Mar
2014, whichever came
first
Excluded cases without
linked birth records
(n = 701), mothers residents
outside NSW (n = 110),
born at 19 weeks of
gestation (n = 3)
K-M 1- and 5-year survival
estimates with 95% CI reported
6
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Table 1. (Continued)
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reference,
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Inclusion of additional
anomalies/exclusions
Reporting of survival estimates Study
quality
total
score�
Schreiber, 2007
[63], Canada
BA 1985–2002 FU up to 10 years, 7%
missing survival data
for 1985–1995, no
missing for 1996–2002
All with confirmed
diagnosis of BA included,
including 27 (14%) with
BASM phenotype
K-M survival estimates with 95%
CI reported for 4 and 10 years
6
Shin, 2012 [46], 10
regions, USA
Spina bifida: 1979–2003 FU to 2004 (up to 20
years for 1983–2003)
for 8 registries, loss to
FU not reported†
Cases with associated
anomalies (e.g., major
CHD) included
K-M 1-, 5-, and 20-year survival
reported for 1983–2003; other:
extracted from K-M curves by
reviewers
6
Siffel, 2003 [47],
Atlanta, USA
Encephalocele 1979–1998 FU 1979–1999 (for
survivors censored at
31 Dec 1999); loss to
FU not reported†
Excluded 8 cases: trisomy
13 (1), trisomy 18 (1),
amniotic bands (3), coded
with ‘possible’ diagnosis (3);
with other major CAs
included (n = 17)
K-M survival estimates reported
for 1, 5, and 20 years—overall and
by risk factor
6
Simmons, 2014
[20], Texas, USA
Achondroplasia 1996–2005 FU to 31 Dec 2007 up
to age 10 years
(minimal 2-year FU for
all patients), none lost
to FU
All with confirmed
diagnosis of achondroplasia
included
Mortality reported, 2-year survival
with 95% CI estimated by
reviewers (no censoring, as all FU
to age 2 years)
6
Sutton, 2008 [44],
Dublin, Ireland
Spina bifida, encephalocele 1976–1987 Retrospective data
collection between Aug
1989 and Apr 1990 for
5-year survival (1.1%
[n = 6] lost to FU)
Excluded: those with
anencephaly and with spina
bifida occulta; infants lost to
FU immediately after birth
(n = 6)
K-M 1- and 5-year survival
estimates (no 95% CI) reported
6
Tennant, 2010
[15], Northern
England
All anomalies, by group
and subtype
1985–2003 FU to 29 Jan 2008, up
to 20 years; 99% traced
(10,850/10,964)
Excluded individuals with
unavailable data on survival
status (114; 1%); those with
chromosomal anomalies
outside the EUROCAT
range (ICD codes Q940-59)
K-M survival estimates with 95%
CI reported for EUROCAT CA
groups and subtypes for 1, 5, 10,
15, and 20 years
6
Tu, 2015 [59],
South Australia
BA 1989–2000 The median FU period
13.4 years (IQR, 6.2–
18.2; range 0.6–21), no
loss to FU
Excluded 2 patients, as the
initial KP was performed
interstate
K-M 5-year survival estimates with
95% CI reported by authors for
both overall survival and NLS
6
Wang, 2011 [40],
New York state,
USA
All anomalies and by
group
1983–2006 FU to end 2008 for up
to 25 years (assuming
alive if no death by 31
Dec 2008), loss to FU
not reported
Only Congenital
Malformations Registry
cases matched to their birth
certificates (97%) included
(n = 57,002), cases with
additional anomalies
included
K-M survival estimates with 95%
CI reported for selected CA groups
and subtypes for 1, 5, 15, and 25
years
5
Wang, 2015 [41],
12 states, USA
All anomalies and by
group
1999–2007 FU to end 2008
(ranging from 1 to 9
years), loss to FU not
reported
All live births with a major
CA included (n = 98,833);
infants with multiple defects
were included in each
relevant birth defect
category
K-M survival estimates with 95%
CI reported for selected CA groups
and subtypes for <1, <2, and <8
years
5
Wildhaber, 2008
[64], Switzerland
BA 1994–2004 Median FU 58 months
(range 5–124); no loss
to FU
All patients, including those
with associated anomalies,
were included: BASM
(n = 4), other associated
anomalies or disease (n = 6)
K-M 5-year survival estimates
(overall and NLS) with SE
reported, 95% CI calculated by
reviewers
6
(Continued)
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Survival of children with different congenital anomalies
Table 2 shows survival estimates overall and by birth cohort, where reported, for individuals
up to 25 years of age for studies estimating survival for all congenital anomalies combined and
by different group/type. S5 Table presents more detail for studies reporting survival estimates
by other risk factors (e.g., ethnicity or presence of additional anomalies). Most studies reported
1- and 5-year survival estimates only. Survival varied considerably according to anomaly;
therefore, survival estimates are presented by different groups and subtypes (Table 2). The
5-year survival for all anomalies combined varied from 85% to 95%, owing to different inclu-
sion and exclusion criteria. It was not considered appropriate to pool survival estimates for all
congenital anomalies combined, because of the diversity of the contributing congenital anom-
aly groups.
Congenital anomalies of the nervous system
Survival in live births with anencephaly analysed by four studies was extremely low and varied
from 0% [15,42] to 7.3% [40] by year 1 (Table 2).
Seven studies of survival in children born with spina bifida [6,15,40–42,45,48] including
7,422 live births were summarised in a meta-analysis, with pooled survival estimates of 92%,
91%, 89%, and 88% at ages 5, 10, 20, and 25 years predicted for children born in 2020
(Table 3). Survival has improved significantly over time, with an increased OR per 10-year
increase in birth year 1.34 (95% CI 1.24–1.46, p< 0.001) (Table 3 and Fig 2).
Four studies [15,40,41,47] reported survival of 1,562 encephalocele live births, with pooled
survival estimates of 72%, 72%, 71%, and 71% at ages 5, 10, 20, and 25 years predicted for
infants born in 2020 (Table 3). A small decrease in survival was observed over time, which was
not statistically significant (p = 0.19) but was included in the model predictions to be consis-
tent with the models for other congenital anomalies and acknowledging that the power from
analysing only 4 studies is very low (Table 3 and S1 Fig).
Survival in individuals with hydrocephalus was reported in four studies, with the three
more recent studies reporting very similar survival rates at age 5 years [15,40,42] and at 15
years in two studies with longer follow-up. The earlier study (1967–1979) reported lower sur-
vival of 50.8% for male individuals by age 18 years [8] (Table 2). Comparison of survival
between these studies is difficult owing to differences in the inclusion criteria.
Table 1. (Continued)
Author,
publication year,
reference,
location
Congenital anomaly (CA)
group/subtype
Birth year
period
Duration and
completeness of
follow-up (FU)
Inclusion of additional
anomalies/exclusions
Reporting of survival estimates Study
quality
total
score�
Wong, 2001 [48],
Atlanta, USA
Spina bifida 1979–1994 FU 1979–1996, loss to
FU not reported†
Excluded cases associated
with anencephaly or
trisomies 13 or 18
K-M survival estimates with 95%
CI to age 18 years (1, 5, 10, 15, 18)
6
�Study data quality was measured using Newcastle-Ottawa Quality Assessment Scale for cohort studies—maximum 9, maximum 6 for those with no comparison group/
nonexposed cohort. Scores of <5 indicated high risk of bias [95].
†Loss to FU likely to be low as the linkage system for tracing deaths is well established (involving linkage with the National Death Index in the USA studies for deaths
outside the state).
‡Data from Atlanta, USA, are not included, as they are part of the cohort used by Wang and colleagues [41].
https://doi.org/10.1371/journal.pmed.1003356.t001
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Table 2. Survival estimates by congenital anomaly type at age 1–25 years, overall and by birth cohort.
Congenital anomaly group/
subtype
Study and birth year N deaths/
live births
Survival estimates percentage (95% confidence interval [95% CI])
1 year 5 years 10 years 15 years 20 years 25 years
All congenital anomalies
International Classification of
Diseases Revision 9 (ICD-9)
codes 740.0–759.9
Agha, 2006 [6], 1979–
1986, Canada
3620/
45,200
93.4 92.5 92.3 — — —
ICD-9 codes 740–759 Berger, 2003 [7], 1992–
1998, USA
2182/
43,708
95.7 95.0 — — — —
British Paediatric Association
(BPA)-ICD-9 codes 740–759
Dastgiri, 2003 [17], 1980–
1997, Scotland
740/6153 89.11 87.95 — — — —
ICD-8 codes (740–759) Eide, 2006 [8], 1967–1979,
Norway
1169/9186 — — — — 87.4a —
ICD-9 740.00–758.090 Nembhard, 2010 [43],
1996–2003, USA
3518/
48,391
93.7 92.7 — — — —
ICD-10 (Q00-Q99) Tennant, 2010 [15],
1985–2003, Northern
England
1465/
10,850
— — — — 85.5
(84.8–86.3)
—
ICD-9 codes 740–759 Wang, 2011 [40],
1983–2006, USA
9112/
57,002
87.1
(86.8–87.4)
85.2
(84.9–85.5)
— 83.9
(83.6–84.2)
— 82.7
(82.4–83.1)
Neural tube defects
Including anencephaly Dastgiri, 2003 [17],
1980–1997, Scotland
40/144 72.2
(64.9–79.5)b
71.5
(63.8–79.3)b
— — — —
Including anencephaly Schneuer, 2019 [42],
2004–2009, New South
Wales (NSW), Australia
34/110 69.1
(60.5–77.7)
69.1
(60.5–77.7)
— — — —
Including anencephaly Tennant, 2010 [15],
1985–2003, Northern
England
87/226 65.0
(58.4–70.9)
62.8
(56.2–68.8)
62.4
(55.7–68.3)
62.4
(55.7–68.3)
63.4
(53.4–66.7)
—
Excluding anencephaly Sutton, 2008 [44],
1976–1987, Ireland
313/543 43.7 40.8 — — — —
Anencephaly
ICD-9 code 740.0–740.2 Agha, 2006 [6],
1979–1986, Canada
183/ 4.8 4.6 — — — —
Schneuer, 2019 [42],
2004–2009, NSW,
Australia
19/19 0.0 — — — — —
Tennant, 2010 [15],
1985–2003, Northern
England
17/17 0.0 — — — — —
ICD-9 740.0–740.1 Wang, 2011 [40],
1983–2006, USA
447/479 7.3 (5.2–9.9) 6.8 (4.8–9.3) — 6.5 (4.5–9.0) — 6.5 (4.5–9.0)
Spina bifida
ICD-9 code 741.0–741.9 Agha, 2006 [6], 1979–86,
Canada
182/ 78.5 75.3 — — — —
ICD-10 Q05 and ICD-9 741 Bakker, 2019 [49],
2001–2012, Czech
Republic
/139 91.4 90.0 88.6c — — —
Malta Congenital
Anomaly Registry
/28 92.8 92.8 — — — —
Sweden /263 92.5 92.1 91.7c — — —
UK–Wales /78 91.0 89.7 89.7c — — —
USA–Arkansas /177 87.0 84.2 83.1c — — —
USA–Texas /1,578 91.6 90.5 90.1c — — —
USA–Utah /213 90.7 90.7 90.2c — — —
(Continued)
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Table 2. (Continued)
Congenital anomaly group/
subtype
Study and birth year N deaths/
live births
Survival estimates percentage (95% confidence interval [95% CI])
1 year 5 years 10 years 15 years 20 years 25 years
USA–Atlanta, 2001–2008 /112 95.5 95.5 95.5c — — —
Italy–Lombardy,
2003–2012
/25 100.0 96.0 — — — —
Myelomeningocele Borgstedt-Bakke, 2017
[45], 1970–1979, Denmark
16/58 84.5 84.5 82.8 79.4 79.4 —
1980–1989 5/39 97.5 92.4 92.4 92.4 89.8 —
1990–2015 6/90 95.6 95.6 94.5 92.8 92.8 —
Spina bifida (ICD-8 code 741) Eide, 2006 [8], 1967–79,
Norway
56/113 — — — — 50.4a —
Spina bifida Schneuer, 2019 [42],
2004–2009, NSW,
Australia
11/56 80.4
(70.0–90.8)
80.4
(70.0–90.8)
— — — —
ICD-9 741.0 and 741.9 Shin, 2012 [46],
1997–2003, USA
162/2,259 92.8
(91.7–93.8)
— — — — —
1983–1987 87.1 84.5 82.7 80.7 80.4 —
1988–1992 90.4 87.6 86.7 85.7 — —
1993–1997 89.9 88.2 87.2 — — —
1998–2003 92.8 90.8 — — — —
Myelomeningocele and spinal
meningocele
Sutton, 2008 [44], Ireland /373 50.4 47.3 — — — —
Spina bifida, ICD-10 Q05 Tennant, 2010 [15],
1985–2003, Northern
England
63/195 70.8
(63.8–76.6)
69.2
(62.2–75.2)
68.7
(61.6–74.7)
68.7
(61.6–74.7)
66.4
(58.9–72.9)
—
ICD-9 741.0, 741.9 Wang, 2011 [40],
1983–2006, USA
324/1999 88.5
(87.0–89.8)
86.4
(84.8–87.8)
— 83.8
(82.0–85.4)
— 82.2
(80.1–84.0)
Spina bifida without anencephaly Wang, 2015 [41],
1999–2007, USA
318/3903 91.9
(90.9–92.7)
— 90.2
(89.0–91.2)d
— — —
Wong, 2001 [48], USA,
1979–1994
45/235 87.2
(83.1–91.6)
83.8
(79.2–88.6)
80.9
(75.8–86.3)
78.4
(72.4–84.7)
78.4
(72.4–84.7)a
—
1979–1983 83 (75–91) 82 (73–90) 79 (71–88) — 76 (68–86)a —
1984–1988 89 (92–96) 85 (78–93) 81 (73–90) — — —
1989–1994 91 (85–98) 84 (75–94) — — — —
Encephalocele
Siffel, 2003 [47],
1979–1998, USA
25/83 72.2
(62.6–81.9)
70.8
(60.9–80.7)
— — 67.3
(55.7–78.8)
—
Sutton, 2008 [44],
1976–1987, Ireland
/64 32.9 27.3
Tennant, 2010 [15],
1985–2003, Northern
England
7/14 64.3
(34.3–83.3)
50.0
(22.9–72.2)
50
(22.9–72.2)
50
(22.9–72.2)
— —
ICD-9 742.0 Wang, 2011 [40],
1983–2006, USA
171/556 75.7
(71.9–79.1)
72.1
(68.1–75.6)
— 69.7
(65.6–73.4)
— 67.2
(62.7–71.3)
Wang, 2015 [41],
1999–2007, USA
254/909 72.1
(69.0–74.9)
— 69.9
(66.1–73.3)d
— — —
Hydrocephalus
Eide, 2006 [8], 1967–1979,
Norway
29/59 — — — — 50.8a —
Schneuer, 2019 [42],
2004–2009, NSW,
Australia
15/60 75.0
(64.0–86.0)
75.0
(64.0–86.0)
— — — —
(Continued)
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Table 2. (Continued)
Congenital anomaly group/
subtype
Study and birth year N deaths/
live births
Survival estimates percentage (95% confidence interval [95% CI])
1 year 5 years 10 years 15 years 20 years 25 years
Tennant, 2010 [15],
1985–2003, Northern
England
32/108 76.9
(67.8–83.7)
75.0
(65.7–82.1)
71.2
(61.3–79.0)
69.8
(59.6–77.8)
66.4
(54.5–75.9)
—
742.3 Wang, 2011 [40],
1983–2006, USA
1,314/
5,378
82.7
(81.6–83.7)
78.5
(77.4–79.6)
— 75.3
(74.1–76.5)
— 73.4
(72.1–74.7)
Orofacial clefts
Cleft palate and cleft lip
(749.0–749.9)
Agha, 2006 [6],
1979–1986, Canada
188/ 90.2 88.2 — — — —
Orofacial clefts (749.0–749.9) Bell, 2016 [16], 1980–2010,
Western Australia
113/1,509 92.5
(91.0–93.8)
— — — — —
Orofacial clefts 1980–1992 73/585 — 87.5
(84.5–90.0)
— — — —
Cleft lip only (BPA-ICD-
9–749.10–749.19)
1980–2010 for 1 year,
1980–2007 for 5 years;
1980–1992 for 20 years
95.8 (all)
99.7
(isolated)
95.8 (all)
99.7
(isolated)
— — 97.7 (all)
100.0
(isolated)
—
Cleft lip and palate
(749.20–749.27, 749.29)
1980–2010 for 1 year,
1980–2007 for 5 years,
1980–1992 for 20 years
91.2 (all)
99.1
(isolated)
99.1
(isolated)
— — 84.5 (all);
98.0
(isolated)
—
Cleft palate (749.00–749.09) 1980–2010 for 1 year,
1980–1992 for 20 years
91.7 (all)
99.2
(isolated)
— — — 83.5 (all);
97.2
(isolated)
—
Cleft lip with/without palate Dastgiri, 2003 [17],
1980–1997, Scotland
5/278 98.2
(96.8–99.6)b
98.2
(96.6–99.8)b
— — — —
Cleft lip Eide, 2006 [8], 1967–1979,
Norway
6/250 — — — — 97.6a —
Cleft palate 9/151 — — — — 94.0a —
Cleft lip and palate 19/357 — — — — 94.7a —
Orofacial clefts Schneuer, 2019 [42],
2004–2009, NSW,
Australia
7/575 99.0
(98.1–99.8)
98.8
(97.9–99.7)
— — — —
Cleft lip and palate 0/188 100.0 100.0 — — — —
Orofacial clefts Tennant, 2010 [15],
1985–2003, Northern
England
14/584 97.8
(96.2–98.7)
97.8
(96.2–98.7)
97.6
(95.9–98.6)
97.6
(95.9–98.6)
97.6
(95.9–98.6)
—
Cleft lip 1/140 99.3
(95.0–99.9)
99.3
(95.0–99.9)
99.3
(95.0–99.9)
99.3
(95.0–99.9)
99.3
(95.0–99.9)
—
Cleft lip and palate 5/227 98.2
(95.4–99.3)
98.2
(95.4–99.3)
97.7
(94.6–99.1)
97.7
(94.6–99.1)
97.7
(94.6–99.1)
—
Cleft palate 8/217 96.3
(92.8–98.1)
96.3
(92.8–98.1)
96.3
(92.8–98.1)
96.3
(92.8–98.1)
96.3
(92.8–98.1)
—
Cleft lip with or without cleft
palate
6/367 98.6
(96.8–99.4)
98.6
(96.8–99.4)
98.3
(96.3–99.2)
98.3
(96.3–99.2)
98.3
(96.3–99.2)
—
Cleft palate without cleft lip
(ICD-9 749.0)
Wang, 2011 [40],
1983–2006, USA
410/3,719 91.0
(90.0–91.8)
89.6
(88.6–90.6)
— 88.9
(87.8–89.9)
— 88.3
(87.1–89.4)
Cleft lip with/without cleft palate
(ICD-9 749.1–749.2)
454/4,691 91.7
(90.9–92.5)
90.8
(89.9–91.6)
— 90.2
(89.3–91.0)
— 90.0
(89.1–90.8)
Cleft palate without cleft lip Wang, 2015 [41],
1999–2007, USA
660/7,356 91.0
(90.4–91.7)
— 90.3
(89.5–91.1)d
— — —
Cleft lip with or without cleft
palate
999/11,862 91.6
(91.1–92.1)
— 90.8
(90.1–91.4)d
— — —
Digestive system anomalies
Oesophageal atresia
(Continued)
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Table 2. (Continued)
Congenital anomaly group/
subtype
Study and birth year N deaths/
live births
Survival estimates percentage (95% confidence interval [95% CI])
1 year 5 years 10 years 15 years 20 years 25 years
ICD-9 code 750.3 Cassina, 2016 [50],
1981–2012 (all), Northeast
Italy
/330 88.4
(84.9–91.9)
— — — — 85.1
(80.8–89.4)
1981–1996 (isolated) 96.1 94.6 94.6 90.6 90.6 90.6
1997–2012 (isolated) 95.3 95.3 95.3 95.3 — —
1981–1996 (non-isolated) 63.0
(49.1–76.9)e
58.7
(44.4–73.0)
58.7
(44.4–73.0)e
58.7
(44.4–73.0)
58.7
(44.4–73.0)
58.7
(44.4–73.0)
1997–2012 (non-isolated) 88.4
(82.7–94.1)e
87.3
(81.2–93.4)
87.3
(81.2–93.4)e
87.3
(81.2–93.4)
— —
Garne, 2002 [51],
Denmark
11/27 — 59.3
(39.0–77.0)
— — — —
ICD-7 756.21, ICD-8 750.20,
750.28, ICD-9 750D, ICD-10
Q39.0–Q39.2.
Oddsberg, 2012 [9],
1964–2007, Sweden
227/1,126 82.1 80.7 80.6 80.5 80.1
1964–1969 62.1 62.1 62.1 62.1 58.5 58.5
1970–1979 77.2 75.6 75.6 75.2 75.2 75.2
1980–1989 82.5 82.1 81.9 81.9 80.5 —
1990–1999 86.1 85.1 85.1 84.9 — —
2000–2007 87.8 87.6 — — — —
Schneuer, 2019 [42],
2004–2009, NSW,
Australia
0/51 100.0 100.0 — — — —
Tennant, 2010 [15],
1985–2003, northern
England
7/105 95.2
(88.9–98.0)
93.3
(86.5–96.8)
93.3
(86.5–96.8)
93.3
(86.5–96.8)
93.3
(86.5–96.8)
—
ICD-9 750.3 Wang, 2011 [40],
1983–2006, USA
336/1,580 81.5
(79.5–83.4)
79.5
(77.4–81.4)
— 78.6
(76.4–80.5)
— 78.3
(76.1–80.3)
Wang, 2015 [41],
1999–2007, USA
476/3,084 84.6
(83.2–85.8)
— 83.8
(82.1–85.2)d
— — —
Anorectal malformations
ICD-9/BPA 752.1–752.4, cloaca
—751.55
Cassina, 2019 [52],
Northeast Italy, 1990–2012
/253 89.7
(85.2–92.9)
— — — 86.7
(81.6–90.4)
—
Anorectal atresia or stenosis
Tennant, 2010 [15],
1985–2003, Northern
England
2/83 98.8
(91.8–99.8)
98.8
(91.8–99.8)
98.8
(91.8–99.8)
96.6
(86.1–99.2)
96.6
(86.1–99.2)
—
ICD-9 751.2 Wang, 2011 [40],
1983–2006, USA
374/2,654 87.7
(86.4–88.9)
86.5
(85.2–87.8)
— 85.9
(84.5–87.2)
— 84.8
(83.1–86.4)
Wang, 2015 [41],
1999–2007, USA
702/5,400 87.0
(86.1–87.9)
— 86.1
(85.0–87.2)d
— — —
Hirschsprung disease
ICD-7: 756.31, ICD-8: 751.39,
ICD-9: 751D, ICD-10: Q431
Lo¨f Granstro¨m, 2017 [24],
1964–2013, Sweden
22/739 99.3
(98.7–99.8)
98.3
(97.4–99.2)
98.3
(97.4–99.2)
97.9
(96.9–99.0)
97.7
(96.5–98.8)
97.7
(96.5–98.8)
Schneuer, 2019 [42],
2004–2009, NSW,
Australia
5/90 96.7
(93.0–100)
94.4
(89.7–99.2)
— — — —
Tennant, 2010 [15],
1985–2003, Northern
England
4/61 93.4
(83.5–97.5)
93.4
(83.5–97.5)
93.4
(83.5–97.5)
93.4
(83.5–97.5)
93.4
(83.5–97.5)
—
Biliary atresia
Overall survival
Chardot, 2013 [36],
1986–2009, France
228/1,107 — 80.8
(78.4–83.2)
79.7
(77.2–82.2)
78.6
(75.9–81.3)
77.6
(74.5–80.7)
—
(Continued)
PLOS MEDICINE Long-term survival of children with congenital anomalies
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003356 September 28, 2020 18 / 55
Table 2. (Continued)
Congenital anomaly group/
subtype
Study and birth year N deaths/
live births
Survival estimates percentage (95% confidence interval [95% CI])
1 year 5 years 10 years 15 years 20 years 25 years
1986–1996 — 72.1
(68.0–76.2)
— — — —
1997–2002 — 88.0
(84.1–91.9)
— — — —
2003–2009 — 88.5
(84.8–92.2)
— — — —
Davenport, 2011 [37],
1999–2009, England and
Wales
41/443 — 90 (88–93) 89 (86–93) — — —
De Carvalho, 2010 [55],
1982–2008, Brazil
166/513 — 67.6f — — — —
De Vries, 2011 [56], the
Netherlands
1977–1982 32/49 — — — — 34.7
(22.1–49.7)
1983–1988 27/55 — — — — 50.9
(37.2–64.5)
Grizelj, 2010 [57],
1992–2006, Croatia
7/29 — 75.9
(56.1–89.0)
75.9
(56.1–89.0)
— — —
Lampela, 2012 [60],
1987–2010, Finland
27/72 — 62.5
(50.3–73.4)h
— — — —
Leonhardt, 2011 [61],
2001–2005, Germany
31/183 81.9
(75.4–87.0)k
— — — — —
McKiernan, 2000 [39],
1993–1995, UK and
Ireland
14/93 — 85.0
(77.7–92.3)
— — — —
McKiernan, 2009 [38], UK
and Ireland
15/93 — — 83.8
(76.2–91.4)l
— — —
Nio, 2003 [62], Japan
1989 birth year 35/108 — — 66.7 — — —
1989–1994 182/735 — 75.3 — — — —
Pakarinen, 2018 [58],
2005–2016, Nordic
countries
21/158 — 87.3
(80.9–91.9)
86.7
(80.2–91.4)
— — —
Schreiber, 2007 [63],
Canada
1985–2002 81/349 77 (72–92)h 75 (70–80) — — —
1985–1995 55/199 74 (67–79)h — — — —
1996–2002 26/150 82 (75–88)h — — — —
Tennant, 2010 [15],
1985–2003, Northern
England
3/14 85.7
(53.9–96.2)
85.7
(53.9–96.2)
— — — —
Tu, 2015 [59], 1989–2000,
South Australia
13/29 — 89.7
(71.5–97.3)
— — — —
Wildhaber, 2008 [64],
1994–2004, Switzerland
4/48 91.5
(83.5–99.5)k
91.5
(83.5–99.5)
91.5
(83.5–99.5)
— — —
Biliary atresia
Survival with native liver (NLS)
Chardot, 2013 [36],
1986–2009, France
(99
+ 542)g/
1,035
— 40.0
(36.9–43.1)
35.8
(32.7–38.9)
32.1
(28.8–35.4)
29.6
(25.7–33.5)
—
(Continued)
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Table 2. (Continued)
Congenital anomaly group/
subtype
Study and birth year N deaths/
live births
Survival estimates percentage (95% confidence interval [95% CI])
1 year 5 years 10 years 15 years 20 years 25 years
1986–1996 — 38.2
(32.9–43.5)
— — — —
1997–2002 — 43.1
(37.0–49.2)
— — — —
2003–2009 — 39.0
(32.5–45.5)
— — — —
Davenport, 2011 [37],
1999–2009, England and
Wales
(24
+ 179)g/
424
— 46 (41–51) 40 (34–46) — — —
De Carvalho, 2010 [55],
1982–2008, Brazil
(94
+ 165)g/
392
— 36.8h — — — —
De Vries, 2011 [56], the Netherlands
1977–1982 (31 + 8)g/
49
— — — — 20.4
(10.7–34.8)g
—
1983–1988 (21 + 16)g/
55
— — — — 32.7
(21.0–46.8)g
—
Grizelj, 2010 [57],
1992–2006, Croatia
(6 + 6)/28 — 51.7
(40.6–62.8)
38.8
(24.9–52.7)
— — —
Lampela, 2012 [60],
1987–2010, Finland
(19 + 25)/
72
— 38.9
(27.8–51.1)h
— — — —
Leonhardt, 2011 [61],
2001–2005, Germany
(28
+ 105)/167
20.4
(14.7–27.4)k
— — — — —
McKiernan, 2000 [39],
1993–95, UK and Ireland
(14 + 33)/
93
— 49.5
(39.0–60.0)
— — — —
McKiernan, 2009 [38], UK
and Ireland
(10 + 42)/
93
— — 43.8
(33.3–54.1)l
— — —
Nio, 2003 [62], Japan
1989 birth year 51/108 — — 52.8 — — —
1989–1994 /735 — 59.7 — — — —
Pakarinen, 2018 [58],
2005–2016, Nordic
countries
72/154 — 53 (45–62) 45 (35–55) — — —
Schreiber, 2007 [63],
Canada
(81
+ 169)/349
33 (28–38)h 24 (19–29) — — —
1985–1995 (55 + 98)/
199
31 (31–38)h — — — —
1996–2002 (26 + 71)/
150
36 (28–45)h — — — —
Tu, 2015 [59], 1989–2000,
South Australia
— 55.2
(36.0–73.0)
— — — —
Wildhaber, 2008 [64],
1994–2004, Switzerland
(4 + 27)/
48
40.5
(26.0–55.0)k
32.7
(18.6–46.8)
— — — —
CDHo
ICD-9 756.6, ICD-10 Q79.0 and
Q79.1
Burgos, 2017 [23],
1987–2013 (all fatalities)
314/861 65.4
(62.1–68.5)
63.5
(60.2–66.7)m
— — — —
1987–1999 (all fatalities) 210/480 56.3
(51.7–60.7)m
— — — —
2000–2013 (all fatalities) 104/381 72.7
(67.9–77.1)m
— — — —
Garne, 2002 [51],
1980–1993
10/17 — 41.2
(19.4–66.5)
— — — —
(Continued)
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Table 2. (Continued)
Congenital anomaly group/
subtype
Study and birth year N deaths/
live births
Survival estimates percentage (95% confidence interval [95% CI])
1 year 5 years 10 years 15 years 20 years 25 years
Gudbjartsson, 2008 [53],
1983–2002, Iceland
8/23 — 65.2
(42.8–82.8)j
— — — —
BPA code 756.610 Hinton, 2017 [18],
1979–2003, USA
Overall survival (up to 20 years, minimum of 3 years
for all cases)
<1988 22/37 — — 40.5
(23.4–57.6)
— 40.5
(23.4–57.6)
—
�1988 41/113 — — 58.3
(46.0–70.6)
— — —
Jaillard, 2003 [54],
1991–1998, France
34/85 60.0
(48.9–70.3)j
— — — — —
Schneuer, 2019 [42],
2004–2009, NSW,
Australia
24/90 73.3
(64.2–82.5)
73.3
(64.2–82.5)
— — — —
Tennant, 2010 [15],
1985–2003, Northern
England
69/161 58.4
(50.4–65.6)
57.1
(49.1–64.4)
57.1
(49.1–64.4)
57.1
(49.1–64.4)
57.1
(49.1–64.4)
—
ICD-9 756.6 Wang, 2011 [40],
1983–2006, USA
586/1,541 63.5
(61.0–65.8)
62.6
(60.1–64.9)
— 62.1
(59.6–64.5)
— 61.4
(58.8–63.8)
Wang, 2015 [41],
1999–2007, USA
1,017/
3,248
68.7
(67.1–70.3)
— 68.0
(66.0–69.9)d
— — —
Limb anomalies
Limb reduction defects
Schneuer, 2019 [42],
2004–2009, NSW,
Australia
5/52 90.4
(82.4–98.4)
90.4
(82.4–98.4)
— — — —
Upper-limb reduction
Tennant, 2010 [15],
1985–2003, Northern
England
1/111 100.0 99.1
(93.8–99.9)
99.1
(93.8–99.9)
99.1
(93.8–99.9)
99.1
(93.8–99.9)
—
ICD-9 755.2 Wang, 2011 [40],
1983–2006, USA
199/1,752 90.7
(89.2–92.0)
89.4
(87.9–90.8)
— 89.0
(87.4–90.4)
— 87.7
(85.8–89.4)
Wang, 2015 [41],
1999–2007, USA
387/3,602 89.3
(88.2–90.2)
— 88.2
(86.9–89.4)d
— — —
Lower-limb reduction
Tennant, 2010 [15],
1985–2003, Northern
England
3/42 92.9
(79.5–97.6)
92.9
(79.5–97.6)
92.9
(79.5–97.6)
92.9
(79.5–97.6)
92.9
(79.5–97.6)
—
ICD-9 755.3 Wang, 2011 [40],
1983–2006, USA
136/1,044 88.6
(86.5–90.4)
87.3
(85.2–89.2)
— 87.1
(84.9–89.0)
— 86.7
(84.4–88.6)
Wang, 2015 [41],
1999–2007, USA
219/1,913 88.6
(87.0–89.9)
— 88.2
(86.4–89.8)d
— — —
Abdominal wall defects
Abdominal wall defects Eide, 2006 [8], 1967–1979,
Norway
72/206 — — — — 65.0a —
Schneuer, 2019 [42],
2004–2009, NSW,
Australia
14/139 90.6
(85.8–95.5)
89.9
(84.9–94.9)
— — — —
Gastroschisis
(Continued)
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Table 2. (Continued)
Congenital anomaly group/
subtype
Study and birth year N deaths/
live births
Survival estimates percentage (95% confidence interval [95% CI])
1 year 5 years 10 years 15 years 20 years 25 years
Surgical code DQ79.3, JAG10 Risby, 2017 [21],
1997–2009, South
Denmark
7/71 93.0
(83.7–97.4)
91.5
(81.9–96.5)
— — — —
Schneuer, 2019 [42],
2004–2009, NSW,
Australia
9/109 91.7
(86.6–96.9)
91.7
(86.6–96.9)
— — — —
Tennant, 2010 [15],
1985–2003, Northern
England
12/190 93.7
(89.2–96.4)
93.7
(89.2–96.4)
93.7
(89.2–96.4)
93.7
(89.2–96.4)
93.7
(89.2–96.4)
—
ICD-9 756.73 Wang, 2011 [40],
1983–2006, USA
116/777 87.8
(85.3–89.9)
85.5
(82.8–87.8)
— 84.8
(82.0–87.2)
— 81.7
(74.0–87.3)
Wang, 2015 [41],
1999–2007, USA
266/3,698 92.8
(91.9–93.6)
— 92.1
(91.0–93.2)d
— — —
Omphalocele
Tennant, 2010 [15],
1985–2003, Northern
England
6/47 87.2
(73.8–94.1)
87.2
(73.8–94.1)
87.2
(73.8–94.1)
87.2
(73.8–94.1)
87.2
(73.8–94.1)
—
ICD-9 756.72 Wang, 2011 [40],
1983–2006, USA
200/639 69.5
(65.8–72.9)
68.8
(65.1–72.3)
— 68.6
(64.9–72.1)
— 68.6
(64.9–72.1)
Wang, 2015 [41],
1999–2007, USA
367/1,281 71.4
(68.8–73.7)
— 71.2
(68.0–74.1)d
— — —
Urinary-system anomalies
ICD-9 753.0–753.9 Agha, 2006 [6],
1979–1986, Canada
451/ 68.8 67.2 — — — —
Dastgiri, 2003 [17],
1980–1997, Scotland
69/618 89.0 88.8 — — — —
Bilateral renal agenesis Schneuer, 2019 [42],
2004–2009, NSW,
Australia
5/5 0.0 — — — — —
Cystic kidney disease 9/83 89.2
(82.5–95.8)
89.2
(82.5–95.8)
— — — —
ICD-10 Q60-Q64 Tennant, 2010 [15],
1985–2003, Northern
England
84/1,258 93.9
(92.4–95.1)
93.5
(86.6–94.2)
93.4
(91.9–94.6)
93.2
(91.6–94.5)
93.2
(91.6–94.5)
—
Bilateral renal agenesis 21/21 0.0 — — — — —
Cystic kidney disease 20/225 92.0
(87.6–94.9)
91.1
(86.6–94.2)
91.1
(86.6–94.2)
91.1
(86.6–94.2)
91.1
(86.6–94.2)
—
Renal agenesis or dysgenesis—
ICD-9 753.0
Wang, 2011 [40],
1983–2006, USA
693/1,946 66.1
(63.9–68.1)
64.8
(62.6–66.9)
— 64.2
(62.0–66.3)
— 63.8
(61.6–66.0)
Down syndrome
759.3 (ICD-8), 758.0 (ICD-9) and
Q90.0, Q90.1, Q90.2 or Q90.9
(ICD-10)
Brodwall, 2018 [22],
1994–2009, Norway
78/1,251 96.3 94.2 — — — —
1994–1999 94.2b 91.8e — — — —
2000–2009 97.5b 95.8e — — — —
758.0 (ICD-9) Chua, 2020 [71],
1995–2014, Hong Kong
83/1,010 94.4
(92.7–95.7)
91.8b
(89.9–93.4)
— — — —
Dastgiri, 2003 [17],
1980–1997, Scotland
33/210 87.1
(82.6–91.7)b
84.3
(78.3–90.3)b
— — — —
Frid, 1999 [65],
1973–1980, Sweden
54/213 85.4
(79.8–89.8)
77.4 76.5
(70.1–81.9)
74.6
(68.2–80.2)i
Glasson, 2016 [66],
1953–2010, Western
Australia
245/1,378 — 88 (86–90) 87 (85–89) — — 83 (80–85) at
30 years
1980–2010 78/772
(Continued)
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Table 2. (Continued)
Congenital anomaly group/
subtype
Study and birth year N deaths/
live births
Survival estimates percentage (95% confidence interval [95% CI])
1 year 5 years 10 years 15 years 20 years 25 years
1980–1990 93 (89–96) 86 (81–89) 85 (80–89) 84 (79–88) 82 (77–87)
1991–2000 97 (94–99) 96 (92–98) 95 (91–97) 94 (90–96) 94 (90–96)
2001–2010 96 (92–98) 94 (90–96) 94 (90–96) 94 (90–96) 94 (90–96) 94 (90–96)
Halliday, 2009 [67],
Australia
1988–1990 25/236 94.1 89.4 — — — —
1998–2000 10/165 94.5 93.9 — — — —
Hayes, 1997 [68],
1980–1989, Ireland
63/389 88.2 (85–91) 83 (79–87) 83 (79–87) — — —
1980–1984 87 82 — — — —
1985–1989 90 86 — — — —
BPA codes, or both BPA and
ICD-9-CM, or ICD9-CM only
(North Carolina and Colorado)
Kucik, 2013 [19],
1983–2003 (20-year
survival), USA
1,584/
16,506
92.9
(92.5–93.2)
91.0
(90.5–91.4)
90.7
(90.2–91.1)
— 88.1
(87.0–89.0)
—
1983–1989 (20-year
survival)
334/2,454 91.3
(90.0–92.4)
88.1
(86.8–89.3)
87.4
(86.0–88.6)
— 85.7
(84.1–87.1)
—
1990–1996 (10-year
survival)
624/5,441 91.2
(90.5–92.0)
89.2
(88.3–90.0)
88.4
(87.6–89.3)
— — —
1997–2003 (5-year
survival)
608/8,611 94.3
(93.8–94.8)
92.5
(91.9–93.0)
— — — —
Leonard, 2000 [69],
1980–1996, Western
Australia
/440 91.7
(88.7–94.0)
87.0
(83.0–89.0)
85.0
(81.0–89.0)
— — —
1980–1985 89 80 (72–86)e 79 — — —
1986–1990 92 86 (79–91)e 85 — — —
1991–1996 94 93 (88–96)e — — — —
Q900–Q902 Rankin, 2012 [14],
Northern England,
1985–1990
54/235 86.0
(80.8–89.8)
79.2
(73.4–83.8)
78.3
(72.5–83.0)
— 77.5
(71.6–82.3)
—
1991–1996 36/193 83.9
(78.0–88.4)
82.4
(76.2–87.1)
81.9
(75.7–86.6)
— 80.6 —
1997–2003 21/241 94.2
(90.4–96.5)
91.7
(87.4–94.6)
91.2
(86.8–94.2)
— 90.7 —
ICD-9-CM (758.000–758.090) Rasmussen, 2006 [70],
1979–1998, USA
70/645 92.9
(90.9–94.9)
89.9
(87.3–92.1)
88.6
(85.0–92.2)
— 87.4
(84.3–90.5)
—
Schneuer, 2019 [42],
2004–2009, NSW,
Australia
30/425 94.1
(91.9–96.4)
92.9
(90.5–95.4)
— — — —
ICD-9 758.0 Wang, 2011 [40],
1983–2006, USA
754/6,819 92.0
(91.3–92.6)
89.9
(89.1–90.6)
— 88.9
(88.1–89.7)
— 87.5
(86.5–88.5)
Wang, 2015 [41],
1999–2007, USA
944/15,939 94.1
(93.7–94.4)
— 92.8
(92.3–93.2)d
— — —
Trisomy 13
Meyer, 2016 [72],
1999–2007, USA
625/693 11.5
(9.3–14.1)
9.7 (7.2–12.5) — — — —
ICD-9, 758.1 or ICD-10,
Q91.4–Q91.7
Nelson, 2016 [25],
1991–2012, Canada
/174 19.8
(14.2–26.1)
15 (10–21) 12.9
(8.4–18.5)
— — —
Tennant, 2010 [15],
1985–2003, Northern
England
26/29 13.8
(4.4–28.6)
— o — — — —
ICD-9 758.1 Wang, 2011 [40],
1983–2006, USA
437/525 21.3
(17.9–24.9)
18.4
(15.3–21.9)
— 16.2
(13.0–19.7)
15.2
(12.0–18.8)
(Continued)
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Table 2. (Continued)
Congenital anomaly group/
subtype
Study and birth year N deaths/
live births
Survival estimates percentage (95% confidence interval [95% CI])
1 year 5 years 10 years 15 years 20 years 25 years
Trisomy 18
Meyer, 2016 [72],
1999–2007, USA
984/1,113 13.4
(11.5–15.5)
12.3
(10.1–14.8)
— — — —
ICD-9, 758.2 or ICD-10,
Q91.0-Q91.3
Nelson, 2016 [25],
1991–2012, Canada
/254 12.6
(8.9–17.1)
11 (8–16) 9.8
(6.4–14.0)
Schneuer, 2019 [42],
2004–2009, NSW,
Australia
28/34 20.6
(7.0–34.2)
17.6
(4.8–30.5)
— — — —
Tennant, 2010 [15],
1985–2003, Northern
England
62/63 1.6 (0.1–7.5) — o — — — —
ICD-9 758.2 Wang, 2011 [40],
1983–2006, USA
667/773 18.8
(16.1–21.6)
15.2
(12.8–17.8)
— 13.2
(10.9–15.8)
— 12.3
(9.8–15.1)
Skeletal dysplasia
Osteogenesis imperfecta ICD-10
Q78.0
Folkestad, 2016 [13],
1977–2012, Denmark
24/366 (up
to 20
years)
94.8
(91.8–96.8)
94.8
(91.8–96.8)
— — 91.6
(88.2–94.2)
—
Skeletal dysplasia Schneuer, 2019 [42],
2004–2009, NSW,
Australia
15/75 80.0
(70.9–89.1)
80.0
(70.9–89.1)
— — — —
Achondroplasia BPA code
756.430
Simmons, 2014 [20],
1996–2005, USA
4/106 96.2
(90.1–98.8)
96.2
(90.1–98.8)k
— — — —
Achondroplasia/
Hypochondroplasia
Tennant, 2010 [15],
1983–2003, Northern
England
2/22 95.5
(71.9–99.4)
90.9
(68.3–97.7)
90.9
(68.3–97.7)
90.9
(68.3–97.7)
— —
Prader-Willi syndrome
Lionti, 2012 [73],
1950–2010, Australia
15/163 (to
35 years)
98.6
(95.2–99.7)
98.6
(95.2–99.7)
97 (93–99) 96.3
(91.1–98.4)
94 (88–97) 89.4
(80.8–94.5)
ICD-10 Q87.1 Tennant, 2010 [15],
1983–2003, Northern
England
1/10 100.0 90.0
(47.3–98.5)
90.0
(47.3–98.5)
— — —
Congenital anomaly subtypes were presented within the major congenital anomaly groups according to the European Surveillance of Congenital Anomalies
(EUROCAT) classification [26].
Estimates (or 95% CI) in italics were not reported in the article but were estimated from the raw data provided and in italics, and bold values were extracted from
Kaplan-Meier or actuarial survival curves. For calculation of 95% CIs, we used the efficient-score method (corrected for continuity) described by Newcombe, 1998 [29],
based on the procedure outlined by Wilson, 1927 [30].
a18-year survival values.
bProvided by authors on request or confirmed by authors.
cSurvival at �5 years reported.
d8-year survival values.
ep-Values < 0.05.
fOverall survival reported, including all deaths (also without operation or liver transplantation), without specifying age at survival.
gDeaths and secondary liver transplantation used in calculation of NLS.
h4-year survival values.
i14.5-year survival values.
j3-year survival values.
k2-year survival values.
l13-year survival values.
mOverall survival (beyond 1 year of age) for all live births reported.
nThis article (Rankin, 2012 [14]) was included despite being a subset of the larger study analysing all types of congenital anomalies (Tennant and colleagues [15])
because it reported survival by year period and explored predictors of survival. To avoid duplication in reporting, survival for Down syndrome from Tennant and
colleagues [15] was included in neither the tables of this review nor the meta-analysis.
oSurvival not reported as <5 cases at risk at the end of the time period.
https://doi.org/10.1371/journal.pmed.1003356.t002
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Table 3. Predicted survival estimates for children born with selected congenital anomalies in 2000 and 2020 (results of the meta-analysis).
Congenital anomaly subtype (n
of studies)
Survival
period
Survival estimates for infants
born in 2000, %
Survival estimates for infants
born in 2020, %
Trend in survival over time
Relative odds (95% confidence
interval)
p-Value
Spina bifida (n = 7) 1.34 (1.24–1.46)� <0.001
1 year 88 (87–89) 93 (91–94)
5 years 87 (86–88) 92 (90–94)
10 years 86 (84–87) 91 (89–93)
20 years 82 (80–85) 89 (86–92)
25 years 81 (77–83) 88 (84–91)
Encephalocele (n = 4) 0.98 (0.95–1.01)� 0.19
1 year 73 (73–74) 73 (71–74)
5 years 73 (73–74) 72 (71–74)
10 years 73 (72–74) 72 (70–74)
20 years 72 (71–73) 71 (69–74)
25 years 72 (71–73) 71 (68–74)
Oesophageal atresia (n = 7) 1.50 (1.38–1.62)� <0.001
1 year 86 (85–87) 93 (92–94)
5 years 86 (85–87) 93 (91–94)
10 years 85 (84–87) 93 (91–94)
20 years 85 (82–87) 92 (90–94)
25 years 84 (82–87) 92 (89–94)
Biliary atresia (n = 14)
Overall survival 1.62 (1.28–2.05)� <0.001
1 year 87 (85–90) 95 (90–97)
5 years 85 (81–89) 94 (87–97)
10 years 82 (74–87) 92 (83–97)
20 years 73 (59–84) 88 (70–96)
Survival with native liver 0.96 (0.88–1.03)� 0.26
1 year 44 (41–47) 41 (35–48)
5 years 43 (38–47) 41 (33–49)
10 years 42 (36–48) 40 (30–50)
20 years 40 (31–50) 38 (26–52)
Congenital diaphragmatic hernia
(n = 9)
1.57 (1.37–1.81)� <0.001
1 year 67 (66–69) 84 (78–88)
5 years 67 (65–69) 83 (78–88)
10 years 67 (64–69) 83 (77–88)
20 years 66 (63–69) 83 (76–88)
25 years 66 (62–69) 83 (75–88)
Gastroschisis (n = 5)
1 year 90 (90–91) 94 (90–96) 1.24 (1.02–1.50)� 0.029
5 years 90 (89–91) 93 (89–96)
10 years 89 (87–91) 93 (88–96)
20 years 88 (84–90) 92 (85–95)
Down syndrome (n = 10)
With congenital heart defect
(CHD)
1.99 (1.67–2.37)� < 0.001
1 year 92 (91–93) 98 (97–99)
5 years 90 (88–92) 97 (95–99)
(Continued)
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Orofacial clefts
Seven studies providing survival estimates for children born with orofacial clefts [6,15–17,40–-
42] included 32,492 live births. There was insufficient number of studies reporting data by spe-
cific cleft type that met criteria for a meta-analysis; therefore, the survival data are presented in
Table 2. Generally, 1-year and long-term survival of children with isolated cleft lip is over 99%
[15,16], about 96%–97% for isolated cleft palate [15,16] and much lower for non-isolated oro-
facial cleft types [40,41].
Anomalies of the digestive system
Seven studies reporting survival in children with oesophageal atresia (n = 6,303) were summa-
rised in a meta-analysis [9,15,40–42,50,51]. There was a statistically significant improvement
in survival over time, with an increased OR of 1.50 (95% CI 1.38–1.62, p< 0.001) per 10-year
increase in birth year. The pooled survival estimates predicted for infants born in 2020 were
93%, 93%, 92%, and 92% at ages 5, 10, 20, and 25 years, respectively (Table 3 and Fig 3).
The survival estimates for children with anorectal malformations and for those with Hirsch-
sprung disease were reported in four [15,40,41,52] and three studies [15,24,42] with survival
ranging between 86% and 97% and between 93% and 98%, respectively (Table 2).
Fourteen studies (n = 3,877 live births) reporting overall (after Kasai hepatoportoenterost-
omy [KP]) and/or liver transplantation) and/or survival with native liver (NLS, without liver
transplantation) in children born with biliary atresia [15,36–38,55–64] were included in the
meta-analysis. Pooled overall survival for biliary atresia at ages 5, 10, and 20 years were esti-
mated to be 94%, 92%, and 88% for infants born in 2020 (Table 3). Fig 4 and Table 3 show a
significant linear increasing trend in the overall survival and ORs for improvement in survival
over time with OR = 1.62 (95% CI 1.28–2.05, p< 0.001). A small decrease in survival was
observed over time in NLS, which was not statistically significant (p = 0.26) but was included
in the model predictions to be consistent with the models for other congenital anomalies
(Table 3). The predicted 5-year survival estimate was 41% (95% CI 33–49) for infants born in
2020 (the survival curve is shown in S2 Fig).
Table 3. (Continued)
Congenital anomaly subtype (n
of studies)
Survival
period
Survival estimates for infants
born in 2000, %
Survival estimates for infants
born in 2020, %
Trend in survival over time
Relative odds (95% confidence
interval)
p-Value
10 years 88 (84–92) 97 (93–98)
20 years 87 (76–93) 96 (90–99)
Without CHD 1.17 (0.91–1.5)� 0.23
1 year 97 (96–98) 98 (95–99)
5 years 96 (95–98) 97 (94–99)
10 years 96 (92–98) 97 (91–99)
20 years 95 (85–98) 96 (82–99)
Trisomy 18 (n = 4) Not tested
1 year 15 (14–17)
5 years 14 (12–16)
10 years 13 (11–16)
�Per 10-year increase compared to any previous birth cohort.
https://doi.org/10.1371/journal.pmed.1003356.t003
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Fig 2. Survival estimates (with 95% confidence intervals) of children with spina bifida at 1 (a), 5 (b), and 10 (c) years of age over
time (10 birth cohorts from 7 studies). The numbers at survival points indicate the included study, which may appear more than
once if survival was reported for more than one birth cohort: 1 –Agha, 2006, Canada; 2 –Borgstedt-Bakke, 2017, western Denmark; 3
–Wong, 2001, Atlanta, USA; 4 –Tennant, 2010, Northern England; 5 –Wang, 2011; USA, 6 –Wang, 2015, USA; 7 –Schneuer, 2019,
New South Wales, Australia.
https://doi.org/10.1371/journal.pmed.1003356.g002
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Fig 3. Survival estimates (with 95% confidence intervals) of children with oesophageal atresia at 1 (a) and 5 (b) years of age
over time (7 studies). The numbers at survival points indicate the included study: 1 –Cassina, 2016, Northeast Italy; 2 –Garne, 2002,
Funen, Denmark; 3 –Oddsberg, 2012, Sweden; 4 –Tennant, 2010, Northern England; 5 –Wang, 2011 USA; 6 –Wang, 2015, USA; 7
–Schneuer, 2019, New South Wales, Australia.
https://doi.org/10.1371/journal.pmed.1003356.g003
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Fig 4. Survival estimates (with 95% confidence intervals) of children with biliary atresia at 5 (a) and 10 (b) years of age over time
(11 birth cohorts from 9 studies). The numbers at survival points indicate the included study which may appear more than once if
survival was reported for more than one birth cohort: 1 –McKiernan, 2000, UK and Ireland; 3 –Nio, 2003, Japan; 6 –Tennant, 2010,
Northern England; 8 –Wildhaber, 2008, Switzerland; 9 –Davenport, 2011, England and Wales, 10 –Chardot, 2013, France; 11
–Pakarinen, 2018, Nordic countries; 13 –Grizelj, 2010, Croatia; 15 –Tu, 2015, South Australia.
https://doi.org/10.1371/journal.pmed.1003356.g004
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Nine studies of children born with CDH (n = 6,176) were summarised in a meta-analysis
[15,18,23,40–42,51,53,54]; pooled survival estimates of 83% at ages 5, 10, 20, and 25 years
respectively predicted for infants born in 2020 were reported in Table 3. The studies demon-
strated that the majority of deaths occurred within the first year of life, with survival plateauing
after that. Survival has improved significantly over time, with an increased OR per 10-year
increase in birth year of 1.57 (95% CI 1.37–1.81, p< 0.001) (Table 3 and Fig 5).
Abdominal wall defects
Five studies (n = 4,845) reporting survival of children born with gastroschisis were summa-
rised in a meta-analysis [15,21,40–42]. There was a statistically significant improvement in sur-
vival over time, with an increased OR of 1.24 (95% CI 1.02–1.50, p = 0.029) per 10-year
increase in birth year. Similar to studies on CDH, the majority of deaths occurred within the
first year of life, with survival plateauing after that. The pooled survival estimates predicted for
children born in 2020 were 94%, 93%, and 92% at ages 5, 10, and 20 years, respectively
(Table 3 and Fig 6). Survival was consistently higher for gastroschisis than omphalocele in the
three register-based studies reporting survival for both conditions [15,40,41] (Table 2).
Chromosomal anomalies: Trisomies 21, 13, and 18
Survival of children born with Down syndrome (trisomy 21) reported by the presence of CHD
in 10 studies (22,317 live births) [14,19,22,42,65–70] was summarised in the meta-analysis. We
found significantly increasing survival trends over time for children with Down syndrome
associated with CHD (OR = 1.99, 95% CI 1.67–2.37, p< 0.001) per 10-year increase in birth
year; Table 3 and Fig 7). Children with Down syndrome without CHD had relatively high sur-
vival for live births in 2000 with no statistically significant improvement over time predicted
for those born in 2020 (OR = 1.17, 95% CI 0.91–1.5, p = 0.23) (Table 3 and Fig 8). As there was
a significant improvement in children with Down syndrome with CHD, the estimated
improvement in children without CHD (although not statistically significant) was also mod-
elled. For children born in 2020, pooled survival for Down syndrome at ages 5, 10, and 20
years were estimated to be 97%, 97%, and 96% for those both with and without CHD.
Studies analysing long-term survival in children with trisomies 13 (n = 4) and 18 (n = 5)
reported consistently low 1-year survival ranging from 12% [72] to 21% [40] for trisomy 13
and from 2% [15] to 20.6% [42] for trisomy 18 (Table 2). However, large studies from the USA
and Canada have shown that the majority of those individuals who survived to 1 year were
alive at 5 [72], 10 [25], and 15 [40] years. A Canadian study reported that 76% and 65% of
1-year survivors with trisomy 13 were alive at 5 and 10 years, respectively; the corresponding
figures for trisomy 18 were 90% and 77% [25]. In a USA study, conditional 5-year survival (for
those who survived the first year of life) was over 80% for both trisomies 13 and 18 [72]. Four
studies (n = 2,174) reporting survival of children born with trisomy 18 were summarised in a
meta-analysis [25,40,42,72]. The pooled survival estimates predicted for children born in 2020
were 14% and 13% at ages 5 and 10 years, respectively (Table 3 and S3 Fig). The time trends
were not tested, owing to a very small size of the most recent study reporting higher survival.
Other congenital anomalies
Fewer studies analysing survival in children born with limb anomalies, renal anomalies, and
skeletal dysplasias and syndromes met our inclusion criteria, with four being register-based
studies that analysed a range of main anomaly groups/subtypes [15,40–42] (Table 2).
Survival of children born with upper or lower-limb defects was similar at about 87%–89%
at 5 and 8 years of age in both USA register-based studies that included isolated anomalies and
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Fig 5. Survival estimates (with 95% confidence intervals) of children with congenital diaphragmatic hernia at 1 (a) and 5 (b)
years of age over time (5 studies). The numbers at survival points indicate the included study: 2 –Garne, 2002, Denmark; 6
–Tennant, 2010, Northern England; 7 –Wang, 2011, USA; 8 –Wang, 2015, USA; 9 –Schneuer, 2019, New South Wales, Australia.
https://doi.org/10.1371/journal.pmed.1003356.g005
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Fig 6. Survival estimates (with 95% confidence intervals) of children with gastroschisis at 1 (a) and 5 (b) years of age over time
(5 studies). The numbers at survival points indicate the included study: 1—Risby, 2017, southern Denmark; 2—Schneuer, 2019,
New South Wales, Australia; 3—Tennant, 2010, Northern England; 4—Wang, 2011, USA; 5—Wang, 2015, USA.
https://doi.org/10.1371/journal.pmed.1003356.g006
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Fig 7. Survival estimates (with 95% confidence intervals) of children with Down syndrome associated with congenital heart
defect at 1 (a), 5 (b), and 10 (c) years of age over time (11 birth cohorts from 10 studies). The numbers at survival points indicate
the included study, which may appear more than once if survival was reported for more than one birth cohort: 1 –Glasson, 2016,
Western Australia; 2 –Hayes, 1997, Ireland; 3 –Kucik, 2013, USA; 4 –Leonard, 2000, Western Australia; 5 –Rankin, 2012, Northern
England; 6 –Rasmussen, 2006, Atlanta, USA; 10 –Brodwall, 2018, Norway; 11 –Frid, 1999, northern Sweden; 12 –Halliday, 2009,
Victoria, Australia, 13 –Schneuer, 2019, New South Wales, Australia.
https://doi.org/10.1371/journal.pmed.1003356.g007
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Fig 8. Survival estimates (with 95% confidence intervals) of children with Down syndrome without congenital heart defect at 1
(a), 5 (b), and 10 (c) years of age over time (11 birth cohorts from 10 studies). The numbers at survival points indicate the included
study, which may appear more than once if survival was reported for more than one birth cohort: 1 –Glasson, 2016, Western
Australia; 2 –Hayes, 1997, Ireland; 3 –Kucik, 2013, USA; 4 –Leonard, 2000, Western Australia; 5 –Rankin, 2012, Northern England; 6
–Rasmussen, 2006, Atlanta, USA; 10 –Brodwall, 2018, Norway; 11 –Frid, 1999, northern Sweden; 12 –Halliday, 2009, Victoria,
Australia, 13 –Schneuer, 2019, New South Wales, Australia.
https://doi.org/10.1371/journal.pmed.1003356.g008
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those with additional anomalies [40,41], whereas survival for upper-limb defects was higher at
99% than that for lower-limb defects at 93%% after 1 year of age in an English register-based
study that included only isolated anomalies [15]. However, the latter study was much smaller,
with�3 deaths for these anomalies.
Survival of children with urinary-system anomalies is not comparable between the studies,
because of the differences in inclusion criteria (isolated versus non-isolated) and different
birth year periods (Table 2).
Four studies reporting survival/mortality for children with skeletal dysplasia beyond 1 year
of age were quite heterogeneous in terms of subtypes included, which may have caused differ-
ences in survival between a recent Australian study [42] and three other studies [13,15,20].
Two studies reported survival in patients with PWS, but the sample size was very low
(n = 10, with one death) in one [15]. According to an Australian study using data from the
PWS register, 10-year survival (97%) was similar to 1-year survival (98.6%); however, by age
25 it reduced to 89% [73].
Factors associated with survival of children with congenital anomalies
Table 4 shows that overall, long-term survival in children born with congenital anomalies was
much lower than in the reference populations, with the risks of death varying from 6.7 to 12.9
times greater than in the general population in the three studies reporting this [6–8]. In the
USA study, the hazard ratio (HR) of death at age 7 years was only slightly reduced (from 7.2 to
6.9) when adjusted for child’s sex and mother’s race, age, and education [7] (Table 4). Table 4
also shows risks of death associated with some specific congenital anomalies compared to the
reference population.
Studies analysing survival predictors reported the presence of additional major anomalies
as a universal risk factor of reduced survival
[9,14,19,22,36,37,40,44,46,47,50,52,65,66,68,69,71,72] (Table 5), even after adjustment for such
factors as birth cohort, birth weight, and/or gestational age at delivery [9,14,19,40,44,50,69,72]
(Table 5). Other common risk factors associated with survival in children with congenital
anomalies had a low birth weight (LBW) [9,14,19,40,47,48,50,52,66,69,71] or preterm birth
[14,40,42,72] and earlier birth year period, after adjustment for covariates
[9,14,19,40,50,66,69,71] (Table 5). Ethnicity was inconsistently associated with survival of chil-
dren with some anomalies in USA studies. Hispanic ethnicity was associated with reduced sur-
vival by age 8 years in children with spina bifida weighing at birth between 1,500 and 2,499 g,
but not in those with lower (<1,500 g) or higher (�2,500 g) birth weight [46]. In another mul-
tistate USA study [41], there was no significant association of spina bifida survival at�8 years
with any ethnic group when adjusted for covariates (Table 5, S6 Table). However, the latter
study reported a significantly increased adjusted HR for reduced survival in Black and His-
panic children for both orofacial clefts and those with oesophageal atresia after adjustment for
essential covariates and significantly increased adjusted HR for Down syndrome and CDH in
Black children only [41] (S6 Table). Black ethnicity, however, was associated with a lower risk
of death at 5 years for trisomy 18 [72]. In New York state, maternal nativity (‘Others’ versus
‘US born’) was significantly associated with a higher risk of death up to 25 years for all congen-
ital anomalies and for anomalies of the central nervous system when adjusted for other factors
including ethnicity [40]. Being aboriginal had a significant independent effect on reduced
10-year survival of children with Down syndrome in an earlier Australian study after adjust-
ment for presence of CHD, birth weight, and birth cohort [69], but not in a more recent study
[66] (Table 5).
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Because of the rarity of biliary atresia and dependence of outcome on successful and timely
KP, the survival factors most commonly explored in these children were annual centre case-
load [36,38,39,58,61] and age at KP [36,37,55,56,58,63,64]. The higher centre caseload—i.e.,
care centralisation associated with centralisation of surgical and medical resources and better
surgical staff experience—and earlier age at KP were considered as positive factors for survival.
Earlier KP was associated with better NLS at age 4 years [55,63,64] and 5 years [58]. The
20-year NLS was also higher for children operated at a younger age compared to>90 days in a
French study [36] and to>75 days in a Dutch study [56]. However, 10-year NLS was not asso-
ciated with age at KP in a UK study [37]. Centre caseload (<5 versus >5) was the only signifi-
cant factor for both 5-year overall survival and NLS in an earlier UK study after adjustment for
confounders [39], but at 13 years it remained a significant factor for NLS only [38]. Centre
caseload (<3 versus >3) was also a significant predictor of 5-year NLS in a collaborative Scan-
dinavian study [58], and in Finland centralisation of care for patients with biliary atresia signif-
icantly increased both overall and NLS to age 4 years [60] (Table 5). In a French study, lower
centre caseload was significantly associated with both reduced overall survival and NLS in the
Table 4. Risk of death in children born with a congenital anomaly (CA) compared to the reference population.
Study CA group/
subtype
Length of survival
for prediction
analysis
Presence
of CA
Unadjusted odds ratio (OR)/hazard
ratio (HR)/relative risk (RR)/
standardised mortality ratio (SMR)
survival (95% CI)
Adjusted HR (aHR)
(95% confidence
interval [95% CI])
Factors adjusted for
Agha, 2006 [6] All CAs 10 years for all, up
to 17 years for birth
year 1979
Yes RR 12.9 (12.1–13.7) — —
Berger, 2003
[7]
All CAs 7 years Yes HR 7.2 (6.9–7.6) aHR 6.9 (6.6–7.3) Race, sex, mother’s age,
mother’s education
Eide, 2006 [8]� All CAs 18 years Yes RR 6.7 (6.3–7.1) — —
Spina bifida 18 years Yes 26.4 (21.9–31.8) — —
Cleft lip 18 years Yes 1.3 (0.6–2.8) — —
Clef palate 18 years Yes 3.2 (1.7–6.0) — —
Cleft lip and
palate
18 years Yes 2.8 (1.8–4.4) — —
Abdominal wall
defect
18 years Yes 18.6 (15.4–22.4) — —
Multiple 18 years Yes 24.0 (21.7–26.5) — —
Bell, 2016 [16] Cleft lip only
(isolated)
1 year Yes OR 0.56 (0.08–4.12) — —
Cleft palate only
(isolated)
1 year Yes OR 1.50 (0.45–4.96) — —
Cleft lip and
palate (isolated)
1 year Yes OR 1.37 (0.41–4.52) — —
Folkestad,
2016 [13]
Osteogenesis
imperfecta
18 years Yes HR 66.1 (15.7–278.7) aHR 68.1 (16.2–287.3) Comorbidity
Lo¨f
Granstro¨m,
2017 [24]
Hirschsprung
disease
50 years Yes HR 4.77 (2.87–7.91) aHR 3.6 (2.04–6.37) Down syndrome
Oddsberg,
2012 [9]
Oesophageal
atresia
40 years Yes SMR 11.8 (10.3–13.5) — Matched with the
background population by
calendar year, sex, and age
�Selected anomalies only are presented.
https://doi.org/10.1371/journal.pmed.1003356.t004
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Table 5. Predictors of survival/mortality in the included studies that explored factors associated with long-term survival at different age points beyond 1 year of
life.
Study Congenital anomaly (CA)
group/subtype
Risk factor category Unadjusted odds ratio (OR)/
hazard ratio (HR)/ relative
risk (RR)/survival rate (%)
(95% confidence interval
[95% CI])
Adjusted HR (aHR)/
OR (aOR)/RR (95%
CI)
Factors adjusted for
Presence of additional anomalies (isolated versus non-isolated)
Agha, 2006 [6] All CAs Number of anomalies — 10-year aRR Gestational age (GA), birth weight
(BW), maternal age, number of
previous stillbirths
1 1.0 (ref)
2 3.3 (3.1–3.7)
3 6.8 (6.2–7.6)
�4 13.8 (12.7–15.0)
Wang, 2011
[40]
All CAs� — Infant sex, BW, GA, plurality,
number of CAs, parity, maternal
ethnicity, nativity and education,
birth year period25–year aHR
Isolated 1.0 (ref)
Non-isolated 2.8 (2.7–3.0)c
Shin, 2012
[46]
Spina bifida 1-year survival 8-year aHRa Ethnicity, birth cohort
1500-2499g group:
Presence of major
congenital heart
defect (CHD)
81.9 (75.4–86.8) 2.6 (1.3–5.0)c
�2500g: 3.6 (2.1–6.1)c
No 93.8 (92.6–94.7)f 1.0 (ref)
Wong, 2001
[48]
Spina bifida 18-year survival Maternal ethnicity, BW, location of
the lesionMultiple defects 59.0 (42–84) aHR not reported
No 81.9 (76–88)d Not significant (NS)
(results not reported)
(yes versus no)
Siffel, 2003
[47]
Encephalocele 20-year HR 20-year aHR BW, race, birth cohort, GA
Isolated 1.0 (ref) 1.0 (ref)
Non-isolated 3.8 (1.7–8.6)e 2.8 (1.2–6.7)c
Cassina, 2016
[50]
Oesophageal atresia 25-year survival 25-year aHR Birth period, BW
Isolated 91.8 (86.9–96.7c 1.0 (ref)
Non–isolated 79.2 (72.9–85.5) 2.8 (1.3–6.0)d
Oddsberg,
2012 [9]
Oesophageal atresia 40-year HR 40-year aHR Sex, BW, birth year period
Any CA 4.7 (3.5–6.3) 4.9 (3.7–6.6)
Circulatory CA 5.4 (3.9–7.5) 5.6 (4.0–7.8)
Noncirculatory CA 4.2 (3.0–5.8) 4.5 (3.2–6.2)
None 1.0 (ref) 1.0 (ref)
Cassina, 2019
[52]
Anorectal malformations HR — —
�2 associated CAs 7.9 (2.2–27.8)d
No 1.0 (ref)
Chardot, 2013
[36]
Biliary atresia (BA) 20-year native liver survival
(NLS) (%)
RR for 20-year NLS Anatomical type, age at Kasai
operation
BA splenic
malformation
syndrome (BASM)
15.1 (SE=4.6) 1.0 (ref)
No 31.2 (SE=2.3)f 0.59 (0.45–0.78)e
(Continued)
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Table 5. (Continued)
Study Congenital anomaly (CA)
group/subtype
Risk factor category Unadjusted odds ratio (OR)/
hazard ratio (HR)/ relative
risk (RR)/survival rate (%)
(95% confidence interval
[95% CI])
Adjusted HR (aHR)/
OR (aOR)/RR (95%
CI)
Factors adjusted for
Hinton, 2017
[18]
Congenital diaphragmatic
hernia (CDH)
20-year HR 20-year aHR Treatment era, neighbourhood
povertyNon-isolated 2.08 (1.24–3.48) 2.06 (1.22–3.49)
Isolated 1.0 (ref) 1.0 (ref)
Brodwall,
2018 [22]
Down syndrome — 5-year aHR Year of birth
Down syndrome (no
additional CAs)
1.0 (ref)
Extracardiac
malformation (ECM),
CHD or a
combination
Ranging from 2.6 (0.6–
12) for ECM to 28
(8.9–88) for
conotruncal CHD and
ECM
Chua, 2020
[71]
Down syndrome
—
5-year aHR Age and sex
CHD present 1.9 (1.2–3.0)c
No 1.0 (ref)
Glasson, 2016
[66]
Down syndrome 25-year HR 25-year aHR Sex, aboriginality, birth cohort
CHD present 2.9 (1.7–4.9)e 3.1 (1.8–5.3)e
No 1.0 (ref) 1.0 (ref)
Hayes, 1997
[68]
Down syndrome 10-yr survival RR Leukaemia (only significant
variables in the bivariate model, i.e
CAVD and leukaemia were included
in the in the Cox proportional
hazards model)No 90% 1.0 (ref)
Complete atrio-
ventricular defect
(CAVD) present
58% 5.6 (3.2–9.7)e
Kucik, 2013
[19]
Down syndrome — 20-year aHR Race/ethnicity, BW, maternal age
and education, birth period, and
region of birth
CHD present 2.7 (2.4–3.0)c
No 1.0 (ref)
Leonard, 2000
[69]
Down syndrome 10-year HR 10-year aHR Aboriginality, BW, maternal age,
sex, birth cohortCHD present 3.4 (2.0–5.9) 3.7 (2.1–6.7)d
No 1.0 (ref) 1.0 (ref)
Rankin, 2012
[14]
Down syndrome 20-year aHR Birth year, maternal age, GA, Index
of Multiple Deprivation (IMD),
karyotype, plurality, infant sex, BW
None 1.0 (ref) 1.0 (ref)
CHD only 3.8 (2.4–6.0)e 5.0 (3.1–8.1)e
Digestive only 5.1 (2.1–12.4) 6.5 (2.6–16.1)e
CHD and digestive
only
8.8 (3.3–18.0)e 7.8 (3.8–16.4)e
Other(s) 3.5 (1.2–10.0)c 5.1 (1.7–15.1)d
Schneuer,
2019 [42]
Down syndrome 5-year survival — —
None 93.7 (90.5–96.9)
CHD 92.0 (88.3–95.8)g
Meyer, 2016
[72]
Trisomy 18 1-year survival 5-year aHR GA, maternal ethnicity, plurality,
sex, presence of omphalocele, State,
geographical area
CHD 5.7 (3.0–9.6)g 1.3 (1.1–1.6)c
No 15.0 (12.8–17.4) 1.0 (ref)
Omphalocele 3.2 (1.4–13.0)c 1.6 (1.1–2.3)c Same confounders, except for
presence of CHD instead of
omphalocele
No 13.8 (11.8–16.0) 1.0 (ref)
Birth year
(Continued)
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Table 5. (Continued)
Study Congenital anomaly (CA)
group/subtype
Risk factor category Unadjusted odds ratio (OR)/
hazard ratio (HR)/ relative
risk (RR)/survival rate (%)
(95% confidence interval
[95% CI])
Adjusted HR (aHR)/
OR (aOR)/RR (95%
CI)
Factors adjusted for
Wang, 2011
[40]
All CAs� — 25-year aHR Infant sex, BW, GA, plurality,
number of CAs, parity, maternal age,
ethnicity, nativity and education.
1982-1988 1.8 (1.6–1.9)c
1989-1994 1.5 (1.4–1.6)c
1995-2000 1.3 (1.2–1.4)c
2001-2006a 1.0 (ref)
Borgstedt-
Bakke, 2017
[45]
Myelomeningocele HR (overall risk of death up
to 25 years)
— —
Time trend 1990-2015
versus 1970-1979 and
1980-1989
0.7 (0.5–1.0), p=0.05
Shin, 2012
[46]
Spina bifida Birth year
(1979-2003)
— 8-year aHR
NS for any BW groups
Ethnicity, presence of CHD
Siffel, 2003
[47]
Encephalocele 20-year HR 20-year aHR BW, race, GA, presence of associated
CAs1989-98 0.5 (0.2–1.2)g 0.4 (0.2–1.0)
1979-88 1.0 (ref) 1.0 (ref)
1989-98 0.3 (0.01–0.9)c (for
<2500g);
NS for�2500)
Cassina, 2016
[50]
Oesophageal atresia 10-year survival (non-isolated
only)
25-year aHR BW, presence of additional
anomalies
1997+ 87.3 (81.2–93.4)d 1.0 (ref)
Before 1997 58.7 (44.4–73.0) 2.4 (1.3–4.8)d
Oddsberg,
2012 [9]
Oesophageal atresia — aHR (risk of death up
to 40 years)
Sex, additional anomalies, BW
1964-69 4.6 (2.3–9.2)
1970-79 3.1 (2.0–4.7)
1980-89 2.1 (1.4–3.2)
1990-99 1.2 (0.8–1.8)
2000-2007 1.0 (ref)
Cassina, 2019
[52]
Anorectal malformations 1990-1999 4.7 (1.8–11.8)d — —
2000-2012 1.0 (ref)
Lo¨f
Granstro¨m,
2017 [24]
Hirschsprung disease 50-year OR — —
1964-80 1.0 (ref)
1981-2000 0.6 (0.1–4.2)g
2001-2013 0.4 (0.1–3.3)g
Hinton, 2017
[18]
CDH 20-year HR 20-year aHR Neighbourhood poverty, presence of
additional CAs<1988h 1.9 (1.3–3.3) 2.1 (1.3–3.6)
�1988 1.0 (ref) 1.0 (ref)
Chua, 2020
[71]
Down syndrome — 5-year aHR Age and sex
1995-1999 1.0 (ref)
2000-2004 0.4 (0.2–0.8)c
2005-2009 0.5 (0.3–1.0)c
2010-2014 0.5 (0.3–1.0)g
(Continued)
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Table 5. (Continued)
Study Congenital anomaly (CA)
group/subtype
Risk factor category Unadjusted odds ratio (OR)/
hazard ratio (HR)/ relative
risk (RR)/survival rate (%)
(95% confidence interval
[95% CI])
Adjusted HR (aHR)/
OR (aOR)/RR (95%
CI)
Factors adjusted for
Glasson, 2016
[66]
Down syndrome 25-year HR 25-year aHR Sex, aboriginality, presence of a
CHD1980-1990 2.9 (1.7–5.2)e 2.9 (1.6–5.2)e
1991-2000 0.9 (0.5–1.9)g 0.7 (0.4–1.5)g
2001-2010 1.0 (ref) 1.0 (ref)
Kucik, 2013
[19]
Down syndrome — 20-year aHR Race/ethnicity, BW, maternal age
and education, presence of a CHD
and region of birth
1983-1989 1.0 (ref)
1990-1996 0.6 (0.5–0.8)c
1997-2003 0.5 (0.4–0.7)c
Leonard, 2000
[69]
Down syndrome 10-year HR 10-year aHR Aboriginality, BW, presence of
CHD, maternal age group, sex1991-96 0.4 (0.2–0.8)d 0.3 (0.2–0.7)d
1983-89 1.0 (ref) 1.0 (ref)
Rankin, 2012
[14]
Down syndrome 20-year HR 20-year aHR Presence of additional structural
anomalies, GA, maternal age, BW,
karyotype, IMD, plurality, infant sex
Continuous (between
1985-2003)
0.93 (0.89–0.96)e 0.89 (0.85–0.92)e
Low BW (LBW) or small for GA (SGA)
Agha, 2006 [6] All CAs — 10-year aRR GA, number of birth defects,
maternal age, number of previous
stillbirths
�2500g 2.2 (2.0–2.4)c
2501-3000g 1.0 (ref)
3001-4000g 0.6 (0.5–0.7)
>4000g 0.5 (0.4–0.6)
Wang, 2011
[40]
All CAs� — 25-year aHR Infant sex, plurality, number of CAs,
parity, maternal age, ethnicity,
nativity and education, birth year
period
�37, <1500 4.4 (3.7–5.2)c
�37, 1500-2499 2.9 (2.7–3.1)c
�37, 2500-3999 1.0 (ref)
�37,�4000 0.7 (0.6–0.8)g
Nembhard,
2010 [43]
All CAs 5-year HR 5-year aHR Maternal age, maternal education,
infant sex, border county, and
number of birth defects
Appropriate for GA 1.0 (ref) 1.0 (ref)
SGA 2.6 (2.4–2.8)f 2.1 (1.9–2.2)f
Large for GA 0.6 (0.5–0.7)f 0.6 (0.5–0.7)f
Wong, 2001
[48]
Spina bifida Survival at <18 years Maternal ethnicity, location of the
lesion, presence of multiple defects<1500 33.3 (15–74)
1500-2499 68.2 (53–88)
�2500 82.8 (77–90)
18-year aHR
<2500 2.3 (1.1–4.9)c
�2500 1.0 (ref)
Siffel, 2003
[47]
Encephalocele 20-year HR 20-year aHR Race, birth cohort, GA, presence of
associated CAs<2500g 6.3 (2.7–14.4)f 5.2 (2.7–12.6)f
�2500g 1.0 (ref) 1.0 (ref)
Cassina, 2016
[50]
Oesophageal atresia — 25-year aHR Birth period, presence of additional
anomalies<2500 3.7 (1.7–8.3)d
�2500 1.0 (ref)
Oddsberg,
2012 [9]
Oesophageal atresia — 40-year aHR Sex, additional anomalies, birth year
period<1500 7.0 (4.9–10.1)c
�1500 1.0 (ref)
(Continued)
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Table 5. (Continued)
Study Congenital anomaly (CA)
group/subtype
Risk factor category Unadjusted odds ratio (OR)/
hazard ratio (HR)/ relative
risk (RR)/survival rate (%)
(95% confidence interval
[95% CI])
Adjusted HR (aHR)/
OR (aOR)/RR (95%
CI)
Factors adjusted for
Cassina, 2019
[52]
Anorectal malformations <2500g 6.4 (2.3–17.9)e — —
�2500g 1.0 (ref)
Chua, 2020
[71]
Down syndrome — 5-year aHR Age and sex
<2500g 2.4 (1.2–4.8)c
�2500g 1.0 (ref)
Glasson, 2016
[66]
Down syndrome 25-year HR 25-year aHR Sex, birth cohort, aboriginality,
presence of a CHD<2500 2.3 (1.4–3.7)e 1.8 (1.0–3.1)c
�2500 1.0 (ref) 1.0 (ref)
Kucik, 2013
[19]
Down syndrome — 20-year aHR Race/ethnicity, maternal age and
education, presence of a CHD, birth
period, and region of birth
<1500 8.5 (7.3–9.8)c
1500-2499 1.8 (1.6–2.0)c
�2500 1.0 (ref)
Leonard, 2000
[69]
Down syndrome 10-year HR 10-year aHR Aboriginality, presence of CHD,
maternal age group, sex, birth cohort<2500 2.3 (1.4–4.0)d 2.2 (1.2–3.7)d
�2500 1.0 (ref) 1.0 (ref)
Rankin, 2012
[14]
Down syndrome 20-year HR 20-year aHR Presence of additional structural
anomalies, birth year, maternal age,
GA, birth year, karyotype, IMD,
plurality, infant sex
Continuous BW z-
score
0.88 (0.77–1.0) 0.81 (0.71–0.91)
GA
Agha, 2006 [6] All CAs — 10-year aRR Number of birth defects,
birthweight, maternal age, number
of previous stillbirths
�37 weeks 1.1 (0.99–1.2)
38-40 weeks 1.0 (ref)
>40 weeks 1.2 (1.1–1.3)
Nembhard,
2010 [43]
All CAs 5-year HR 5-year aHR Maternal age, maternal education,
infant sex, border county, and
number of birth defects
�37 weeks 1.0 (ref) 1.0 (ref)
<37 weeks 3.0 (2.8–3.2)f 2.7 (2.5–2.9)f
Schneuer,
2019 [42]
All CAs 5-year survival — —
�37 weeks 95.6 (95.3–96.3)
<37 weeks 79.4 (77.5–81.4)e
Wang, 2011
[40]
All CAs� — 25-year aHR Infant sex, plurality, number of CAs,
parity, maternal age, ethnicity,
nativity and education, birth year
period
<37 w, <1500 4.9 (4.6–5.2)c
<37 w, 1500-2499 2.7 (2.6–2.9)c
<37w, 2500-3999 1.5 (1.4–1.6)c
�37 w, 2500-3999 1.0 (ref)
Siffel, 2003
[47]
Encephalocele 20-year HR — —
<37 weeks 4.7 (2.1–10.5)f
�37 weeks 1.0 (ref)
Glasson, 2016
[66]
Down syndrome 25-year HR 25-year aHR Sex, birth cohort, aboriginality,
presence of a CHD<37 weeks 2.4 (1.5–3.7e 1.9 (1.1–3.3)c
�37 weeks 1.0 (ref) 1.0 (ref)
Rankin, 2012
[14]
Down syndrome 20-year HR 20-year aHR Presence of additional structural
anomalies, birth year, maternal age,
BW, karyotype, IMD, plurality,
infant sex
Continuous (weeks) 0.80 (0.76–0.84)e 0.76 (0.72–0.80)e
(Continued)
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Table 5. (Continued)
Study Congenital anomaly (CA)
group/subtype
Risk factor category Unadjusted odds ratio (OR)/
hazard ratio (HR)/ relative
risk (RR)/survival rate (%)
(95% confidence interval
[95% CI])
Adjusted HR (aHR)/
OR (aOR)/RR (95%
CI)
Factors adjusted for
Meyer, 2016
[72]
Trisomy 18 1-year survival 5-year aHR Sex, maternal ethnicity, plurality,
presence of CHD, presence of
omphalocele, State, geographical
area
<32 weeks 4.9 (2.5–8.4)e 2.7 (2.2–3.4)c
32-36 weeks 9.4 (6.3–13.2) 1.5 (1.2–1.8)c
�37 weeks 17.2 (14.3–20.3) 1.0 (ref)
Meyer, 2016
[72]
Trisomy 13 1-year survival 5-year aHR Sex, maternal ethnicity, State,
geographical area<32 weeks 6.6 (3.1–11.9)e 1.9 (1.5–2.5)c
32-36 weeks 8.1 (5.0–12.1) 1.3 (1.0–1.6)
�37 weeks 15.2 (11.6–19.2) 1.0 (ref)
Ethnicity
Berger, 2003
[7]
All CAs 7-year HR 7-year aHR BW, sex, mother’s age, mother’s
education, number of organ systems
affected
White 1.0 (ref) 1.0 (ref)
Black 1.5 (1.4–1.6)c 1.0 (0.9–1.1)g
Wang, 2011
[40]
All CAs Maternal nativity — 25- year aHR Infant sex, BW, gestational age,
plurality, number of CAs, parity,
maternal age, ethnicity and
education, birth year periodUS born 1.0 (ref)
Other 1.1 (1.03–1.15)c
Nembhard,
2010 [43]
All CAs 5-year HR 5-year aHR Maternal age, maternal education,
infant sex, border county, and
number of birth defects
Non-Hispanic White
(NHW)
1.0 (ref) 1.0 (ref)
Non-Hispanic Black
(NHB)
1.3 (1.6–1.9)f 1.5 (1.4–1.7)f
Hispanic 1.4 (1.3–1.5)c 1.1 (1.01–1.2)c
Wong, 2001
[48]
Spina bifida Survival at <18 years aHR not reported BW, presence of multiple defects,
location of the lesion oWhite 82.8 (76–90)
Black 67.1 (56–81)c NS (Black versus
White)Other 87.5 (63–100)
Wang, 2015
[41]
Spina bifida, encephalocele,
limb deficiencies,
gastroschisis, omphalocele
— 8-year aHR BW and gestational age, maternal
age, birth period, and state
surveillance program
NHB NS
Hispanic NS
Asian/Pacific Islander
(A/PI)
NS
American Indian/
Alaska Native (AI/
AN)
NS
NHW 1.0 (ref)
Cleft palate, cleft lip with/w/
o cleft palate, esophageal
atresia, rectal atresia/stenosis
NHB — p< 0.05 BW and gestational age, maternal
age, birth period, and state
surveillance program
Hispanic p< 0.05
A/PI NS
AI/AN NS
NHW 1.0 (ref)
CDH; Down syndrome NHB — 1.4c BW and gestational age, maternal
age, birth period, and state
surveillance program
Hispanic NS
A/PI NS
AI/AN NS
NHW
(Continued)
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Table 5. (Continued)
Study Congenital anomaly (CA)
group/subtype
Risk factor category Unadjusted odds ratio (OR)/
hazard ratio (HR)/ relative
risk (RR)/survival rate (%)
(95% confidence interval
[95% CI])
Adjusted HR (aHR)/
OR (aOR)/RR (95%
CI)
Factors adjusted for
Shin, 2012
[46]
Spina bifida 1-year survival 8-year aHR Birth year, presence of CHD
White 94.1 (92.6–95.4) 1.0 (ref)
Black 87.8 (82.5–91.6)c NS for any BW groupsg
Hispanic 92.2 (90.3–93.8) 3.7 (1.8–7.8)c for 1500-
2499g group, NS for
other BW groups
Siffel, 2003
[47]
Encephalocele 20-year HR 20-year aHR BW, birth cohort, gestational age,
presence of associated CAsBlack 2.7 (1.1–6.5)c 2.4 (0.95–5.9)g
Other 1.0 (ref) 1.0 (ref)
Glasson, 2016
[66]
Down syndrome 25-year HR 25-year aHR Sex, birth cohort, presence of a CHD
Aboriginal 1.6 (0.7–3.8)g 1.1 (0.5–2.7)g
Non-aboriginal 1.0 (ref) 1.0 (ref)
Leonard, 2000
[69]
Down syndrome 10-year HR 10-year aHR Presence of CHD, BW, maternal age,
sex, birth cohortAboriginal 3.2 (1.4–7.4)d 3.2 (1.3–7.9)d
Non-aboriginal 1.0 (ref) 1.0 (ref)
Kucik, 2013
[19]
Down syndrome — aHR (overall survival –
up to 20 years)
BW, maternal age and education,
presence of a CHD, birth period,
and region of birth.White 1.0 (ref)
Black 1.4 (1.0–1.6)
Hispanic 0.8 (0.7–0.9)c
Other 1.3 (1.1–1.6)c
Meyer, 2016
[72]
Trisomy 18 1-year survival 5-year aHR Gestational age, plurality, sex,
presence of CHD, presence of
omphalocele, State, geographical
area
NHW 13.6 (10.7–16.9) 1.0 (ref)
NHB 17.3 (12.5–22.7)c 0.7 (0.6–0.9)c
Hispanic 10.1 (7.3–13.5) 0.9 (0.8–1.1)
NH A/PI 13.2 (4.8–25.8) 0.8 (0.5–1.2)
Other/unknown 23.3 (10.3–39.4) 1.0 (0.6–1.7)
Maternal age (years)
Agha, 2006 [6] All CAs — 10-year aRR Number of birth defects, gestational
age, birthweight, number of previous
stillbirths
�20 1.2 (1.03–1.3)c
21-34 1.0 (ref)
�35 0.9 (0.8–1.1)
Wang, 2011
[40]
All CAs — 25-year aHR Infant sex, BW, gestational age,
plurality, number of CAs, parity,
maternal ethnicity, nativity and
education, birth year period
�19 1.2 (1.1–1.3)c
20-24 1.1 (1.03–1.2)c
25-29 1.05 (1.0–1.1)g
30-34 1.0 (ref)
�35 1.0 (0.9–1.0)g
Leonard, 2000
[69]
Down syndrome 10-year HR 10-year aHR Aboriginality, presence of CHD, sex,
birth cohort, BW<20 2.8 (1.1–7.1)c 2.4 (0.9–6.1)g
�20 1.0 (ref) 1.0 (ref)
Rankin, 2012
[14]
Down syndrome 20-year HR 20-year aHR Presence of additional structural
anomalies, birth year, BW,
gestational age, karyotype, IMD,
plurality, infant sex
<20 1.25 (0.63–2.49) 0.67 (0.32–1.40)
20-30 1.0 (ref) 1.0 (ref)
>30 0.91 (0.61–1.36)g 1.08 (0.71–1.64)g
Centre annual caseload (BA studies)
(Continued)
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Table 5. (Continued)
Study Congenital anomaly (CA)
group/subtype
Risk factor category Unadjusted odds ratio (OR)/
hazard ratio (HR)/ relative
risk (RR)/survival rate (%)
(95% confidence interval
[95% CI])
Adjusted HR (aHR)/
OR (aOR)/RR (95%
CI)
Factors adjusted for
Chardot, 2013
[36]
BA 1986-1996c 5-year overall survival — —
�20 77.6 (72.1–83.1)
3 to5 61.9 (51.1–72.7)
�2 69.6 (62.5–76.7)
1997-2002 NS
2003-2009 NS
Leonhardt,
2011 [61]
BA 2-yr NLS — —
<5 7.7%
�5 26.4%d
McKiernan,
2000 [39]
BA 5-year RR Caseload - the only
significant factor, RR
not reported
Age at surgery, sex, gestational age,
presence of BASM<5 1.0 (ref)
>5 0.32 (0.11–0.94) (overall
survival)
>5 0.48 (0.28–0.86) (NLS)
McKiernan,
2009 [38]
BA Overall 13-year survival (%) — —
<5 75 (61.6–89.4)
>5 89.5 (81.3–97.7)g
13-year NLS (%)
<5 27.3 (12.3–42.3)
>5 54.0 (40.8–67.2)d
Pakarinen,
2018 [58]
BA 5-year NLS aHR for 5-year NLS Presence of associated CAs, age at
surgery, sex, anatomical type of BA,
presence of BASM, clearance of
jaundice, European ethnicity>3 66 (54–77)
d 3.5 (1.8–6.8)e
<3 44 (32–56) 1.0 (ref)
Age at Kasai hepatoportoenterostomy for NLS (BA studies)
Chardot, 2013
[36]
BA 20-year survival (%) RR for 20-year NLS Anatomical type, presence of BASM
�30 days 38.9 ((SE=7.5)d 0.54 (0.37–0.79)f
31-60 days 31.7 (SE=3.4) 0.58 (0.45–0.75)
61-90 days 28.1 (SE=3.1) 0.74 (0.37–0.79)
>90 days 18.7 (SE=4.8) 1.0 (ref)
Davenport,
2011 [37]
BA <44 days NS for 10-yr NLS — —
44-55 Overall: p=0.34;
56-69 or between two most
different (<44 and 44-55)
groups: p=0.15
70+
De Carvalho,
2010 [55]
BA HR for 4-year NLS — —
�60 days 1.0 (ref)
61-90 1.6 (1.2–2.3)d
>90 1.9 (1.3–2.7)d
De Vries, 2011
[56]
BA 20-year NLS survival (%) — —
<45 days 14±9g (versus 45-60 or 60-75
days)
45-60 33±8g (versus 60-75)
60-75 42±10c (versus >75)
>75 11±6
(Continued)
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earlier period (1986–1996) but not in the later (1992–2002 and 2003–2009) periods [36]
(Table 5).
Discussion
This systematic review and meta-analysis summarise long-term survival for individuals born
with a range of congenital anomalies from population-based studies, covering a total popula-
tion of 367,801 live births with congenital anomalies. This work is part of the ‘EUROlinkCAT:
Establishing a linked European Cohort of Children with Congenital Anomalies’, a collabora-
tive project investigating survival, morbidity, and educational outcomes in children born with
congenital anomalies using population-based data from multiple EUROCAT registries linked
to a number of health and education datasets (https://www.eurolinkcat.eu/). A total of 55 stud-
ies were included in the narrative synthesis, with 41 studies included in meta-analyses. Our
meta-analyses showed predicted 20-year survival for children born in 2020 as 89% for spina
bifida (n = 7 studies), 71% for encephalocele (n = 4), 92% for oesophageal atresia (n = 7), 88%
for biliary atresia (n = 14), 83% for CDH (n = 9), 92% for gastroschisis (n = 5), and 96% for
Down syndrome both with and without CHD (n = 10). As expected, the first year of life was
critical for survival of children with a congenital anomaly, but there remained a gradual
Table 5. (Continued)
Study Congenital anomaly (CA)
group/subtype
Risk factor category Unadjusted odds ratio (OR)/
hazard ratio (HR)/ relative
risk (RR)/survival rate (%)
(95% confidence interval
[95% CI])
Adjusted HR (aHR)/
OR (aOR)/RR (95%
CI)
Factors adjusted for
Pakarinen,
2018 [58]
BA 5-year NLS 5-year aHR Presence of associated CAs; sex;
anatomical type of BA, presence of
BASM, clearance of jaundice,
European ethnicity, centre caseload
< 65 66 (55–78)d 1.5 (0.8–2.9)g
>65 44 (32–56) 1.0 (ref)
Schreiber,
2007 [63]
BA 4-year NLS — —
�30 49 (26–69)f
31-90 36 (28–43)
>90 23 (12–37)
Wildhaber,
2008 [64]
BA 4-year NLS (% ± SE) — —
�45 75 ±15.3
46-75 33.3 ± 10.3
>75 11.3 ± 10.6
Only factors examined in�3 studies are included, n = 33 studies.
�The association with the reported factors was also significant for the following CA groups: central nervous system, orofacial clefts, gastrointestinal, genitourinary,
musculo-skeletal, and chromosomal anomalies, but was not reported for specific CA subtypes.
aOnly predictors with significant results in either unadjusted or adjusted analysis are shown.
bConotruncal defects include Tetralogy of Fallot, double outlet right ventricle, conotruncal ventricular septal defects, aortic hypoplasia, truncus arteriosus, and
interrupted aortic arch.
cp<0.05 (also for those significant associations for which the exact p-value not reported).
dp<0.01.
ep<0.001.
fp<0.0001.
gNS (p�0.05).
hTreatment eras are before 1988 (routine immediate surgical repair) and post-1988 (preoperative stabilisation, delayed surgical repair, and addition of lung-sparing
strategies).
https://doi.org/10.1371/journal.pmed.1003356.t005
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decline in survival beyond infancy that exceeded that of the general population. Our meta-
analyses showed statistically significant improvement in survival over time in those with spina
bifida, oesophageal atresia, biliary atresia, CDH, gastroschisis, and Down syndrome in those
with CHD, but not in those with encephalocele, biliary atresia with a native liver, or Down syn-
drome without CHD. The evidence from individual studies showed that improvement in sur-
vival was not equal for all patient groups, being more pronounced, for example, for a group
with non-isolated anomalies [50] or differing by ethnic group [18]. The commonest significant
independent predictors of reduced survival for any congenital anomaly type were presence of
additional structural anomalies, LBW, and earlier birth year period.
Advances in prenatal diagnosis, neonatal care (including intensive care, standard use of
antenatal steroids, and surfactant therapy for prevention of neonatal mortality and morbidity
in preterm births), early surgical interventions, ECMO, care centralisation, and liver trans-
plantation (for biliary atresia patients) were likely to improve survival in these children. One of
the factors that may have contributed to the improvement in survival of live births with spina
bifida over the last 30 years, reported by individual studies [45,46] and revealed by our meta-
analysis, is the increasing use and accuracy of prenatal diagnosis and the consequent increase
in terminations of pregnancy for fetal anomaly (TOPFAs) for most severe anomaly types. One
of the included studies found an independent association of annual TOPFA rate with increase
in survival [15]. Indeed, there is evidence of an association between the increased TOPFA rates
and reduced live-birth prevalence of congenital anomalies and consequent reduction in infant
mortality [74,75]. Periconceptional folic acid intake or fortification is likely to be another fac-
tor of improving survival by reducing the number of severe types of spina bifida [76].
Advances in neonatal and surgical care, including early neonatal or elective fetal surgery for
spina bifida repair [77,78], may have also contributed to increased long-term survival of these
patients.
In addition to the above listed general advances in prenatal diagnosis and neonatal care
contributing to improvement in survival of children with various types of congenital anoma-
lies, there are specific principles in care of CDH patients that affect survival of these patients.
These are early intubation with avoidance of bag mask ventilation; prevention and treatment
of pulmonary hypertension and lung hypoplasia, the primary causes of neonatal mortality in
CDH patients, by minimising lung damage using gentle lung ventilation (e.g., high-frequency
oscillatory ventilation); gastric decompression, ensuring adequate blood pressure; ECMO, if
indicated; and delayed surgical repair after stabilisation of pulmonary and haemodynamic sta-
tus [79].
Studies of survival of children with biliary atresia, a rare life-limiting progressive disorder of
bile ducts, which is fatal without early surgery (KP) and eventually requires liver transplanta-
tion, were mostly limited to 4–5 years of follow-up, with two European studies reporting sur-
vival at age 20 years [36,56]. Despite a number of existing reviews on biliary atresia, including
a systematic review published in 2013 [80], this condition was included in our review, as we
aimed to update the existing evidence on a population base and pool data in a meta-analysis.
The 4-year NLS was as low as 23.5% before centralisation of care (1987–2005) in Finland,
increasing to 76% after centralisation [60]. In addition to centralised care, earlier age at KP
was a predictor of better NLS in these patients in some studies [36,55,56,58,63,64], which was
in agreement with an earlier systematic review [80]. However, in the UK centre, caseload was
the only significant factor associated with better NLS at age 5, 10, or 14 years [37–39]. Care
centralisation and liver transplantation are crucial factors in the care of these patients, increas-
ing the overall 10-year patient survival to 79.7% in France [36] and 87%, 89%, and 91.5% in
the Scandinavian countries [58], UK [37], and Switzerland [64], respectively.
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A significant association between birth year and increase in survival of individuals with
Down syndrome was reported in some reviewed studies [14,19,66,69]. Recent advances in
intensive care of preterm and very LBW babies are likely to account for prevention of infant
death in many children with Down syndrome who are at a 2-fold higher risk of infant death
compared to very LBW babies without a congenital anomaly, owing to higher risk of infection
and lung disease such as bronchopulmonary dysplasia [81]. Improved access to early cardiac
surgery in infants with septal defects may have also contributed to their increased long-term
survival by prevention of development of pulmonary arterial hypertension and Eisenmenger
syndrome, the conditions of high-risk mortality [66,82,83]. Our meta-analysis has shown that
survival estimates significantly increased over time for children with CHD, but the improve-
ment for those without CHD was not statistically significant.
Until recently, trisomies 13 and 18 were regarded as lethal conditions, with the majority of
prenatally diagnosed cases being electively terminated and those resulting in live births (about
19% and 14% for trisomies 13 and 18, respectively [84]) commonly receiving palliative care
only. Two recent studies that analysed survival of children with trisomy 13 or 18 beyond 1 year
[25,72] demonstrated that although cumulative survival was low, children who were alive at
their first birthday had around an 80% chance of survival to their fifth birthday, and 86% of
those who survived to age 5 were likely to live to age 10 years [25]. Despite the emerging evi-
dence that intensive care and surgical interventions improve the survival in these children
[85], the debate in the medical community in relation to the interventions to be offered to
infants with these trisomies is ongoing [85–87] because of severe cognitive impairment in the
survivors and considerations in relation to family and societal burden [87]. Current medical
experts’ view is that medical care of children with trisomies 13 and 18 should be evidence-
based [85], and more consideration should be given to personalised care of these children, pro-
viding more information to parents and taking into account their hopes and wishes [86].
The commonest significant independent predictors of reduced survival at and beyond 1
year of life for any congenital anomaly type were presence of additional structural anomalies,
LBW, and earlier birth year period. The association with ethnicity was inconsistent in the USA
studies across different anomaly types and aboriginality was significantly associated with
reduced survival in children with Down syndrome in an earlier study [69] but not in a more
recent one [66]. Ethnicity may be a proxy indicator of deprivation, which is associated with
increased neonatal and infant mortality across all major causes of death including congenital
anomalies [88–91]; however, the associations with other deprivation measures were not ana-
lysed in the included studies.
This systematic review and meta-analysis is strengthened by a rigorous search strategy and
comprehensive literature searches using a combination of multiple sources of information to
identify relevant papers. Our systematic search strategy was informed by the research protocol
registered in the PROSPERO database and developed according to clear inclusion criteria
based on elements of the PICOS framework. To ensure that the search strategy was appropri-
ately inclusive, it was piloted using Medline, refined, and retested. Additionally, we manually
searched the reference lists of all included papers, citations of the included papers repeating
that process for newly identified papers, and also key journals in the field. This approach is rec-
ognised to increase the identification of relevant papers [92]. A 10% sample of titles and
abstracts of records was screened by coauthors to enable consistency in study inclusion follow-
ing predefined eligibility criteria. All data were extracted in duplicate by two independent
reviewers to ensure accuracy in the reported results and to minimise subjectivity. Authors
were contacted where more information was required during data extraction. We also used an
established quality-assessment tool as part of the critical appraisal process.
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We restricted the start year for our literature searches to 1995 to make the birth cohorts
used in the studies more comparable in relation to antenatal and neonatal care and treatment
availability/policies and to avoid subsequent differences. In addition, restricting our review to
population-based studies with follow-up from birth reduces bias in death ascertainment.
We used multilevel meta-analytic models to allow for studies reporting the survival of dif-
ferent cohorts of births over several time periods. Importantly, we estimated survival for
infants born in 2020, which will be useful for counselling parents when a congenital anomaly
is diagnosed and for health and social care planning. The gllamm model allows the correlation
of survival over time within a study to be modelled whilst allowing for the random effects from
different studies. As the included studies used differing birth cohorts with their effect on sur-
vival that increased over time, we felt that it would be inappropriate to present I2 heterogeneity
results that is a standard measure of variation between studies, usually clinical trials. We also
did not test for publication bias, as survival studies profoundly differ by their nature from clin-
ical trials where publication bias can be expected due to a higher likelihood of publication of
positive results, which is not the case for survival studies. Moreover, as a number of register-
based studies included in the meta-analysis estimated survival of many different anomaly
groups and types, publication bias for a specific anomaly is unlikely. Owing to the lack of data
in terms of the small number of studies, formal tests for publication bias lack power, and fun-
nel plots were not informative. The paucity of data limits the predictive capabilities of the
models, as shown by the wide confidence intervals on some estimates. A further limitation is
the assumption that improvements in survival in the past will continue to be maintained in the
future. This is a particular issue with Down syndrome children with CHD. There have been
recent dramatic improvements in their survival, but such improvements are unlikely to con-
tinue, and it is likely that their survival will always be slightly lower than that of children with
Down syndrome without CHD. Yet the two models predicted very similar survival for such
children born in 2020.
Meta-analysis was not possible for all studies included in this systematic review, as either
there was an insufficient number of studies reporting survival for the same anomaly subtype
or the studies did not report 95% CI or the number of cases. Moreover, not all studies included
in the meta-analysis of some structural anomalies (e.g., spina bifida, CDH) were consistent in
their exclusion of non-isolated anomalies, which may have accounted for the variability in the
survival estimates. All but one of the included studies were conducted in high-income coun-
tries, which limited generalisability of the results to low-income countries. Lack of relevant
studies from 66 papers identified from our Medline search not restricted to English language,
most of which were from Europe, suggests that population-based studies with long-term fol-
low-up of children with congenital anomalies or linkage studies to identify deaths beyond
infancy are rare in low-income countries.
The papers analysing survival predictors were not systematically searched for; only studies
eligible for this review that also explored predictors were included. We acknowledge that sum-
marised data on survival predictors reported in the reviewed studies are supplementary and
enrich the interpretation of the results but are not a comprehensive review of predictors of
congenital anomaly–related survival. Therefore, the association of survival with some impor-
tant risk factors such as maternal deprivation, shown to be linked to lower infant and child sur-
vival [89,93], including children born with congenital anomalies [94], could have been
underinvestigated in this review.
This systematic review and meta-analysis summarised the existing international evidence
from population-based studies to provide information on long-term survival of children with
selected congenital anomalies and temporal changes in survival. Our findings reveal a wide
variation in survival by congenital anomaly subtype and suggest reduced survival associated
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with many anomaly subtypes compared with the reference population. The meta-analysis has
demonstrated that survival has significantly improved over time for a number of specific con-
genital anomalies. We have also provided predicted survival estimates for children born in
2020. This information has important implications for the planning and delivery of public
health services, specialised medical care, and educational services and is valuable for clinicians,
public health professionals, healthcare providers, and parents. We identified a lack of good-
quality, reasonably sized studies for many congenital anomaly subtypes that prevented estima-
tion of their pooled survival and analysis of trends over time. Future survival studies should
endeavour to use multicentre case data from different parts of the world linked to reliable mor-
tality data with follow-up from birth to avoid selection bias and underascertainment of deaths.
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